WHO Drug Information, Vol. 29, No. 3, 2015                       Recommended INN: List 74




International Nonproprietary Names
for Pharmaceutical Substances (INN)
RECOMMENDED International Nonproprietary Names: List 74
Notice is hereby given that, in accordance with paragraph 7 of the Procedure for the Selection
of Recommended International Nonproprietary Names for Pharmaceutical Substances [Off.
Rec. Wld Health Org., 1955, 60, 3 (Resolution EB15.R7); 1969, 173, 10 (Resolution EB43.R9);
Resolution EB115.R4 (EB115/2005/REC/1)], the following names are selected as
Recommended International Nonproprietary Names. The inclusion of a name in the lists of
Recommended International Nonproprietary Names does not imply any recommendation of
the use of the substance in medicine or pharmacy.
Lists of Proposed (1–109) and Recommended (1–70) International Nonproprietary Names can
be found in Cumulative List No. 15, 2013 (available in CD-ROM only).
Dénominations communes internationales
des Substances pharmaceutiques (DCI)
Dénominations communes internationales RECOMMANDÉES: Liste 74
Il est notifié que, conformément aux dispositions du paragraphe 7 de la Procédure à suivre en
vue du choix de Dénominations communes internationales recommandées pour les
Substances pharmaceutiques [Actes off. Org. mond. Santé, 1955, 60, 3 (résolution EB15.R7);
1969, 173, 10 (résolution EB43.R9); résolution EB115.R4 (EB115/2005/REC/1)]               les
dénominations ci-dessous sont choisies par l’Organisation mondiale de la Santé en tant que
dénominations communes internationales recommandées. L’inclusion d’une dénomination
dans les listes de DCI recommandées n’implique aucune recommandation en vue de
l’utilisation de la substance correspondante en médecine ou en pharmacie.
On trouvera d’autres listes de Dénominations communes internationales proposées (1–109) et
recommandées (1–70) dans la Liste récapitulative No. 15, 2013 (disponible sur CD-ROM
seulement).
Denominaciones Comunes Internacionales
para las Sustancias Farmacéuticas (DCI)
Denominaciones Comunes Internacionales RECOMENDADAS: Lista 74
De conformidad con lo que dispone el párrafo 7 del Procedimiento de Selección de
Denominaciones Comunes Internacionales Recomendadas para las Sustancias
Farmacéuticas [Act. Of. Mund. Salud, 1955, 60, 3 (Resolución EB15.R7); 1969, 173, 10
(Resolución    EB43.R9);     Résolution    EB115.R4      (EB115/2005/REC/1) EB115.R4
(EB115/2005/REC/1)], se comunica por el presente anuncio que las denominaciones que a
continuación se expresan han sido seleccionadas como Denominaciones Comunes
Internacionales Recomendadas. La inclusión de una denominación en las listas de las
Denominaciones Comunes Recomendadas no supone recomendación alguna en favor del
empleo de la sustancia respectiva en medicina o en farmacia.
Las listas de Denominaciones Comunes Internacionales Propuestas (1–109) y
Recomendadas (1–70) se encuentran reunidas en Cumulative List No. 15, 2013 (disponible
sólo en CD-ROM).




                                                                                         385
Recommended INN: List 74                        WHO Drug Information, Vol. 29, No. 3, 2015




 Latin, English, French, Spanish:   Chemical name or description; Molecular formula;
 Recommended INN                    Graphic formula

 DCI Recommandée                    Nom chimique ou description; Formule brute; Formule
                                    développée
 DCI Recomendada
                                    Nombre químico o descripción; Fórmula molecular;
                                    Fórmula desarrollada



 abemaciclibum
 abemaciclib                          N-{5-[(4-ethylpiperazin-1-yl)methyl]pyridin-2-yl}-5-fluoro-
                                      4-[4-fluoro-2-methyl-1-(propan-2-yl)-1H-benzimidazol-
                                      6-yl]pyrimidin-2-amine

 abémaciclib                          N-{5-[(4-éthylpipérazin-1-yl)méthyl]pyridin-2-yl}-5-fluoro-
                                      4-[4-fluoro-2-méthyl-1-(propan-2-yl)-1H-benzimidazol-
                                      6-yl]pyrimidin-2-amine

 abemaciclib                          N-{5-[(4-etilpiperazin-1-il)metil]piridin-2-il}-5-fluoro-
                                      4-[4-fluoro-2-metil-1-(propan-2-il)-1H-benzoimidazol-
                                      6-il]pirimidin-2-amina

                                      C27H32F2N8

                                                    F
                                                                  N                     N
                                         F                                                  N    CH3
                                                              N       N       N
                                                                      H

                                         N
                                              N
                                                        CH3
                                       H3C
                                              H3C


 amiselimodum
 amiselimod                           2-amino-2-{2-[4-(heptyloxy)-
                                      3-(trifluoromethyl)phenyl]ethyl}propane-1,3-diol

 amisélimod                           2-amino-2-{2-[4-(heptyloxy)-
                                      3-(trifluorométhyl)phényl]éthyl}propane-1,3-diol

 amiselimod                           2-amino-2-{2-[4-(heptiloxi)-
                                      3-(trifluorometil)fenil]etil}propano-1,3-diol

                                      C19H30F3NO3
                                                                                            OH
                                                                                                NH2
                                                                                                      OH

                                       H 3C
                                                                          O
                                                                                  CF3




386
WHO Drug Information, Vol. 29, No. 3, 2015                                              Recommended INN: List 74


 atezolizumabum #
 atezolizumab                          immunoglobulin G1-kappa, anti-[Homo sapiens CD274
                                       (programmed death ligand 1, PDL1, PD-L1, B7 homolog 1,
                                       B7H1)], humanized monoclonal antibody;
                                       gamma1 heavy chain (1-448) [humanized VH (Homo
                                       sapiens IGHV3-23*04 (86.70%) -(IGHD)-IGHJ4*01)
                                       [8.8.11] (1-118) -Homo sapiens IGHG1*03 (CH1 R120>K
                                       (215) (119-216), hinge (217-231), CH2 N84.4>A (298)
                                       (232-341), CH3 (342-446), CHS (447-448)) (119-448)],
                                       (221-214')-disulfide with kappa light chain (1’-214’)
                                       [humanized V-KAPPA (Homo sapiens IGKV1-5*01
                                       (87.90%) -IGKJ1*01) [6.3.9] (1'-107') -Homo sapiens
                                       IGKC*01(108'-214')]; dimer (227-227":230-230")-
                                       bisdisulfide

 atézolizumab                          immunoglobuline G1-kappa, anti-[Homo sapiens CD274
                                       (ligand 1 de mort programmée, PDL1, PD-L1, homologue
                                       1 de B7, B7H1)], anticorps monoclonal humanisé;
                                       chaîne lourde gamma1 (1-448) [VH humanisé (Homo
                                       sapiens IGHV3-23*04 (86.70%) -(IGHD)-IGHJ4*01)
                                       [8.8.11] (1-118) -Homo sapiens IGHG1*03 (CH1 R120>K
                                       (215) (119-216), charnière (217-231), CH2 N84.4>A (298)
                                       (232-341), CH3 (342-446), CHS (447-448)) (119-448)],
                                       (221-214')-disulfure avec la chaîne légère kappa (1’-214’)
                                       [V-KAPPA humanisé (Homo sapiens IGKV1-5*01 (87.90%)
                                       -IGKJ1*01) [6.3.9] (1'-107') -Homo sapiens IGKC*01 (108'-
                                       214')]; dimère (227-227":230-230")-bisdisulfure

 atezolizumab                          inmunoglobulina G1-kappa, anti-[Homo sapiens CD274
                                       (ligando 1 de muerte programada, PDL1, PD-L1,
                                       homólogo 1 de B7, B7H1)], anticuerpo monoclonal
                                       humanizado;
                                       cadena pesada gamma1 (1-448) [VH humanizado (Homo
                                       sapiens IGHV3-23*04 (86.70%) -(IGHD)-IGHJ4*01)
                                       [8.8.11] (1-118) -Homo sapiens IGHG1*03 (CH1 R120>K
                                       (215) (119-216), bisagra (217-231), CH2 N84.4>A (298)
                                       (232-341), CH3 (342-446), CHS (447-448)) (119-448)],
                                       (221-214')-disulfuro com la cadena ligera kappa (1’-214’)
                                       [V-KAPPA humanizado (Homo sapiens IGKV1-5*01
                                       (87.90%) -IGKJ1*01) [6.3.9] (1'-107') -Homo sapiens
                                       IGKC*01 (108'-214')]; dímero (227-227":230-230")-
                                       bisdisulfuro

                                       Heavy chain / Chaîne lourde / Cadena pesada
                                       EVQLVESGGG LVQPGGSLRL SCAASGFTFS                  DSWIHWVRQA       PGKGLEWVAW        50
                                       ISPYGGSTYY ADSVKGRFTI SADTSKNTAY                  LQMNSLRAED       TAVYYCARRH       100
                                       WPGGFDYWGQ GTLVTVSSAS TKGPSVFPLA                  PSSKSTSGGT       AALGCLVKDY       150
                                       FPEPVTVSWN SGALTSGVHT FPAVLQSSGL                  YSLSSVVTVP       SSSLGTQTYI       200
                                       CNVNHKPSNT KVDKKVEPKS CDKTHTCPPC                  PAPELLGGPS       VFLFPPKPKD       250
                                       TLMISRTPEV TCVVVDVSHE DPEVKFNWYV                  DGVEVHNAKT       KPREEQYAST       300
                                       YRVVSVLTVL HQDWLNGKEY KCKVSNKALP                  APIEKTISKA       KGQPREPQVY       350
                                       TLPPSREEMT KNQVSLTCLV KGFYPSDIAV                  EWESNGQPEN       NYKTTPPVLD       400
                                       SDGSFFLYSK LTVDKSRWQQ GNVFSCSVMH                  EALHNHYTQK       SLSLSPGK         448

                                       Light chain / Chaîne légère / Cadena ligera
                                       DIQMTQSPSS LSASVGDRVT ITCRASQDVS                  TAVAWYQQKP       GKAPKLLIYS 50
                                       ASFLYSGVPS RFSGSGSGTD FTLTISSLQP                  EDFATYYCQQ       YLYHPATFGQ 100
                                       GTKVEIKRTV AAPSVFIFPP SDEQLKSGTA                  SVVCLLNNFY       PREAKVQWKV 150
                                       DNALQSGNSQ ESVTEQDSKD STYSLSSTLT                  LSKADYEKHK       VYACEVTHQG 200
                                       LSSPVTKSFN RGEC                                                               214

                                       Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro
                                       Intra-H (C23-C104) 22-96         145-201       262-322 368-426
                                                             22''-96'' 145''-201'' 262''-322'' 368''-426''
                                       Intra-L (C23-C104) 23'-88' 134'-194'
                                                            23'''-88''' 134'''-194'''
                                       Inter-H-L (h 5-CL 126) 221-214' 221''-214'''
                                       Inter-H-H (h 11, h 14) 227-227'' 230-230''

                                       N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación
                                       H CH2 N84.4>A (298, 298'):
                                       No N-glycosylation sites/pas de sites de N-glycosylation/ Ningun posición de N-glicosilación




                                                                                                                                         387
Recommended INN: List 74                WHO Drug Information, Vol. 29, No. 3, 2015




 avoralstatum
 avoralstat                    3-{2-[(4-carbamimidoylphenyl)carbamoyl]-4-ethenyl-
                               5-methoxyphenyl}-6-[(cyclopropylmethyl)carbamoyl]
                               pyridine-2-carboxylic acid

 avoralstat                    acide 3-{2-[(4-carbamimidoylphenyl)carbamoyl]-4-éthényl-
                               5-méthoxyphényl}-6-[(cyclopropylméthyl)
                               carbamoyl]pyridine-2-carboxylique

 avoralstat                    ácido 3-{2-[(4-carbamimidoilfenil)carbamoil]-4-etenil-
                               5-metoxifenil}-6-[(ciclopropilmetil)carbamoil]piridina-
                               2-carboxílico

                               C28H27N5O5

                                               O
                                                   N       CO2H
                                           N
                                           H
                                                                  OCH3
                                                   H
                                                   N                CH2

                                H2N                    O

                                      NH




 axalimogenum filolisbacum #
 axalimogene filolisbac        A live attenuated recombinant strain of Listeria
                               monocytogenes (Lm) bacterium bioengineered to secrete
                               an antigen-adjuvant fusion (tLLO-E7) protein consisting of
                               non-hemolytic listeriolysin O (truncated LLO, tLLO) fused
                               to the human papilloma virus-16 (HPV-16) E7 protein,
                               contained within the multi-copy plasmid pGG-55. The
                               bacterial strain used, XFL-7, had been attenuated by
                               excision of the essential transcription activator gene for
                               virulence gene expression prfA (10403S ∆ prfA) and
                               complemented with a mutated, less active prfA to maintain
                               in vivo retention. In plasmid pGG-55, the Lm hly promoter
                               drives the expression of fusion protein tLLO-E7, an
                               approximately 67-kDa protein. The tLLO fragment of the
                               fusion gene codes for the first 440 amino acids of full-
                               length listeriolysin and is genetically fused to the E7 gene
                               using the restriction site XhoI. The plasmid pGG55 is
                               retained in XFL-7 in vivo due to the expression of the
                               mutated PrfA protein.




388
WHO Drug Information, Vol. 29, No. 3, 2015                              Recommended INN: List 74


 axalimogène filolisbac                souche bactérienne vivante atténuée de Listeria
                                       monocytogenes (Lm) recombinante secrétant une protéine
                                       de fusion antigène-adjuvant (tLLO-E7) qui comprend une
                                       listériolysine O non-hémolytique (LLO tronquée, tLLO),
                                       fusionnée à la protéine E7 du papillomavirus humain de
                                       type 16 (HPV-16), contenue dans le plasmide à copies
                                       multiples pGC-55. La souche bactérienne utilisée, XFL-7, a
                                       été atténuée par excision du gène prfA essentiel à
                                       l’activation de la transcription des gènes de virulence
                                       (10403S ∆ prfA) et complémenté par un gène prfA muté,
                                       moins actif, afin de maintenir une rétention in vivo. Dans le
                                       plasmide pGC-55, le promoteur Lm hly contrôle
                                       l’expression de la protéine de fusion tLLO-E7, une protéine
                                       d’approximativement 67 kDa. Le fragment tLLO du gène
                                       de fusion code les premiers 440 acides aminés de la
                                       listériolysine et est génétiquement fusionné au gène E7 en
                                       utilisant le site de restriction XhoI. Le plasmide pGG55 est
                                       retenu dans XFL-7 in vivo par l’expression de la protéine
                                       PrfA mutée.

 axalimogén filolisbac                 Cepa bacteriana viva atenuada de Listeria monocytogenes
                                       (Lm) recombinante secretando una proteína de fusión
                                       antígeno-adyuvante (tLLO-E7) que consiste en una
                                       listeriolisina O no-hemolítica (LLO truncada, tLLO),
                                       fusionada con la proteína E7 del papilomavirus humano de
                                       tipo 16 (HPV-16) contenida en el plásmido multicopia
                                       pGC-55. La cepa bacteriana utilizada, XFL-7, se ha
                                       atenuado por escisión del gen prfA esencial a la activación
                                       de la transcripción de los genes de virulencia (10403S ∆
                                       prfA) y completada por un gen prfA mutado, menos activo,
                                       con el fín de mantener la retención in vivo. En el plásmido
                                       pGC-55, el promotor Lm hly controla la expresión de la
                                       proteína de fusión tLLO-E7, una proteína de
                                       aproximadamente 67 kDa. El fragmento tLLO del gen de
                                       fusión codifica los primeros 440 aminoácidos de la
                                       listeriolisina y se fusiona genéticamente con el gen E7
                                       utilizando el sitio de restricción XhoI. El plásmido pGG55
                                       es retenido en XFL-7 in vivo por la expresión de la
                                       proteína PrfA mutada.




 balixafortidum
 balixafortide                         cyclo[L-alanyl-L-cysteinyl-L-seryl-L-alanyl-D-prolyl-(2S)-2,4-
                                       diaminobutanoyl-L-arginyl-L-tyrosyl-L-cysteinyl-L-tyrosyl-
                                       L-glutaminyl-L-lysyl-D-prolyl-L-prolyl-L-tyrosyl-L-histidyl] (2-
                                       9)-disulfide

 balixafortide                         (2-9)-disulfure de cyclo[L-alanyl-L-cystéinyl-L-séryl-L-alanyl-
                                       D-prolyl-(2S)-2,4-diaminobutanoyl-L-arginyl-L-tyrosyl-
                                       L-cystéinyl-L-tyrosyl-L-glutaminyl-L-lysyl-D-prolyl-L-prolyl-
                                       L-tyrosyl-L-histidyl]

 balixafortida                         (2-9)-disulfuro de ciclo[L-alanil-L-cisteinil-L-seril-L-alanil-
                                       D-prolil-(2S)-2,4-diaminobutanoil-L-arginil-L-tirosil-
                                       L-cisteinil-L-tirosil-L-glutaminil-L-lisil-D-prolil-L-prolil-L-tirosil-
                                       L-histidil]




                                                                                                          389
Recommended INN: List 74                        WHO Drug Information, Vol. 29, No. 3, 2015


                                  C84H118N24O21S2
                                                                                                                        NH2
                                                                                                       H

                                        Ala       Cys        Ser        Ala          D-Pro         N                    Arg
                                          1                                                        H
                                                                                                                O

                                      His      Tyr      Pro      D-Pro           Lys         Gln   Tyr      Cys         Tyr
                                       16                                                              10


 bovhyaluronidasum azoximerum #
 bovhyaluronidase azoximer        hyaluronidase-2 bovine (hyaluronoglucosaminidase-2,
                                  Hyal-2, EC 3.2.1.35) Bos taurus precursor protein linked to
                                  poly{[1-(carboxymethyl)piperazin-1-ium-1,4-diyl
                                  bromide]ethylene-co-[(piperazine-1,4-diyl
                                  1-oxide)ethylene]} by an amido covalent bond

 bovhyaluronidase azoximère       précurseur de la hyaluronidase-2 bovine
                                  (hyaluronoglucosaminidase-2, Hyal-2, EC 3.2.1.35) Bos
                                  taurus lié au poly{[bromure de 1-(carboxyméthyl)pipérazin-
                                  1-ium-1,4-diyl]éthylène-co-[(1-oxyde de pipérazin-
                                  1,4-diyl)éthylène]} par une liaison covalente amide

 bovhialuronidasa azoxímero       precursor de la hialuronidasa-2 bovina
                                  (hialuronoglucosaminidasa-2, Hyal-2, EC 3.2.1.35) Bos
                                  taurus unido al poli{[bromuro de 1-(carboximetil)piperazin-
                                  1-io-1,4-diil]etileno-co-[(1-óxido de piperazin-
                                  1,4-diil)etileno]} por un enlace covalente amida

                                  Hyal-2 Bos taurus seq. (H2N-Enz) / Hyal-2 Bos taurus seq. (H2N-Enz) / Hyal-2 Bos taurus
                                  seq. (H2N-Enz)
                                  MWTGLGPAVT LALVLVVAWA TELKPTAPPI FTGRPFVVAW DVPTQDCGPR 50
                                  HKMPLDPKDM KAFDVQASPN EGFVNQNITI FYRDRLGMYP HFNSVGRSVH 100
                                  GGVPQNGSLW VHLEMLKGHV EHYIRTQEPA GLAVIDWEDW RPVWVRNWQD 150
                                  KDVYRRLSRH LVAIRHPDWP PERVAKEAQY EFEFAARQFM LETLRFVKAF 200
                                  RPRHLWGFYL FPDCYNHDYV QNWETYTGRC PDVEVSRNDQ LAWLWAESTA 250
                                  LFPSVYLEET LASSTHGRNF VSFRVQEALR VADVHHANHA LPVYVFTRPT 300
                                  YSRGLTGLSE MDLISTIGES AALGAAGVIL WGDAGFTTSN ETCRRLKDYL 350
                                  TRSLVPYVVN VSWAAQYCSW AQCHGHGRCV RRDPNAHTFL HLSASSFRLV 400
                                  PSHAPDEPRL RPEGELSWAD RNHLQMHFRC QCYLGWGGEQ CQWDRRRAAG 450
                                  GASGAWAGSH LTGLLAVAVL AFT                                                     473

                                  Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro
                                  47-343 214-230 368-379 373-430 432-441

                                  Glycosylation sites (N) / Sites de glycosylation (N) / Posiciones de glicosilación (N)
                                  Asn-77 Asn-106 Asn-340 Asn-360

                                  Carrier & Hyal-2 (H2N-Enz) / Transporteur & Hyal-2 (H2N-Enz) / Transportador &
                                  Hyal-2 (H2N-Enz)
                                                                        O
                                                      OH                         R

                                         R =       or / ou / o              N+

                                                      NH Enz                         N
                                                                      Br                 x         N        N
                                                                                               O
                                                                                                                y
                                                                                                                    n




 brolucizumabum #
 brolucizumab                     immunoglobulin scFv, anti-[Homo sapiens VEGFA
                                  (vascular endothelial growth factor A, VEGF-A, VEGF)],
                                  humanized monoclonal antibody single chain;
                                  scFv (1-252) [methionyl (1) -humanized V-KAPPA (Homo
                                  sapiens IGKV1-5*01 (87.60%)-IGKJ2*01 E125>T (108),
                                  I126>V (109), K127>L (110) [6.3.12] (2-111) -21-mer
                                  (glycyl-tetrakis(tetraglycyl-seryl)) linker (112-132) -
                                  humanized VH (Homo sapiens IGHV3-66*01 (80.40%)-
                                  (IGHD)-IGHJ1*01 [9.7.13] (133-252)



390
WHO Drug Information, Vol. 29, No. 3, 2015                                              Recommended INN: List 74


 brolucizumab                          immunoglobuline scFv, anti-[Homo sapiens VEGFA
                                       (facteur de croissance A de l’endothélium vasculaire,
                                       VEGF-A, VEGF)], anticorps monoclonal humanisé à
                                       chaîne unique;
                                       scFv (1-252) [méthionyl (1) -V-KAPPA humanisé (Homo
                                       sapiens IGKV1-5*01 (87.60%)- IGKJ2*01 E125>T (108),
                                       I126>V (109), K127>L (110) [6.3.12] (2-111) -21-mer
                                       (glycyl-tétrakis(tétraglycyl-séryl)) linker (112-132) -VH
                                       humanisé (Homo sapiens IGHV3-66*01 (80.40%)-(IGHD)-
                                       IGHJ1*01 [9.7.13] (133-252)

 brolucizumab                          inmunoglobulina scFv, anti-[VEGFA de Homo sapiens
                                       (factor de crecimiento A del endotelio vascular, VEGF-A,
                                       VEGF)], anticuerpo monoclonal humanizado
                                       monocatenario;
                                       scFv (1-252) [metionil (1) -V-KAPPA humanizado (Homo
                                       sapiens IGKV1-5*01 (87.60%)- IGKJ2*01E125>T (108),
                                       I126>V (109), K127>L (110) [6.3.12] (2-111) -21-mer
                                       (glicil-tetrakis(tetraglicil-seril)) conector (112-132) -VH
                                       humanizado (Homo sapiens IGHV3-66*01 (80.40%)-
                                       (IGHD)-IGHJ1*01 [9.7.13] (133-252)
                                       MEIVMTQSPS      TLSASVGDRV       IITCQASEII       HSWLAWYQQK       PGKAPKLLIY        50
                                       LASTLASGVP      SRFSGSGSGA       EFTLTISSLQ       PDDFATYYCQ       NVYLASTNGA       100
                                       NFGQGTKLTV      LGGGGGSGGG       GSGGGGSGGG       GSEVQLVESG       GGLVQPGGSL       150
                                       RLSCTASGFS      LTDYYYMTWV       RQAPGKGLEW       VGFIDPDDDP       YYATWAKGRF       200
                                       TISRDNSKNT      LYLQMNSLRA       EDTAVYYCAG       GDHNSGWGLD       IWGQGTLVTV       250
                                       SS                                                                                  252

                                       Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro
                                       Intra-chain C23 C104 24-89 154-228

                                       N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación
                                       None


 centanafadinum
 centanafadine                         (1R,5S)-1-(naphthalen-2-yl)-3-azabicyclo[3.1.0]hexane

 centanafadine                         (1R,5S)-1-(naphtalén-2-yl)-3-azabicyclo[3.1.0]hexane

 centanafadina                         (1R,5S)-1-(naftalen-2-il)-3-azabiciclo[3.1.0]hexane

                                       C15H15N
                                                                    H
                                                                    N


                                                                            H



 crisaborolum
 crisaborole                           4-[(1-hydroxy-1,3-dihydro-2,1-benzoxaborol-
                                       5-yl)oxy]benzonitrile

 crisaborole                           4-[(1-hydroxy-1,3-dihydro-2,1-benzoxaborol-
                                       5-yl)oxy]benzonitrile

 crisaborol                            4-[(1-hidroxi-1,3-dihidro-2,1-benzoxaborol-
                                       5-il)oxi]benzonitrilo
                                       C14H10BNO3
                                                                                 OH
                                        NC                                      B
                                                                                    O
                                                            O




                                                                                                                                         391
Recommended INN: List 74                 WHO Drug Information, Vol. 29, No. 3, 2015



 dectrekumabum #
 dectrekumab               immunoglobulin G1-kappa, anti-[Homo sapiens IL13
                           (interleukin 13, IL-13)], Homo sapiens monoclonal
                           antibody;
                           gamma1 heavy chain (1-450) [Homo sapiens VH (IGHV3-
                           33*01 (98.00%) -(IGHD)-IGHJ3*02) [8.8.13] (1-120) -
                           IGHG1*03 (CH1 (121-218), hinge (219-233), CH2 (234-
                           343), CH3 (344-448), CHS (449-450)) (121-450)], (223-
                           216')-disulfide with kappa light chain (1'-216') [Homo
                           sapiens V-KAPPA (IGKV3-11*01 (95.80%) -IGKJ2*01)
                           [6.3.11] (1'-109') -IGKC*01 (110'-216')]; dimer (229-
                           229'':232-232'')-bisdisulfide

 dectrékumab               immunoglobuline G1-kappa, anti-[Homo sapiens IL13
                           (interleukine 13, IL-13)], Homo sapiens anticorps
                           monoclonal;
                           chaîne lourde gamma1 (1-450) [Homo sapiens VH
                           (IGHV3-33*01 (98.00%) -(IGHD)-IGHJ3*02) [8.8.13] (1-
                           120) -IGHG1*03 (CH1 (121-218), charnière (219-233),
                           CH2 (234-343), CH3 (344-448), CHS (449-450)) (121-
                           450)], (223-216')-disulfure avec la chaîne légère kappa (1'-
                           216') [Homo sapiens V-KAPPA (IGKV3-11*01 (95.80%) -
                           IGKJ2*01) [6.3.11] (1'-109') -IGKC*01 (110'-216')]; dimère
                           (229-229'':232-232'')-bisdisulfure

 dectrekumab               inmunoglobulina G1-kappa, anti-[ IL13 de Homo sapiens
                           (interleukina 13, IL-13)], anticuerpo monoclonal de Homo
                           sapiens;
                           cadena pesada gamma1 (1-450) [VH de Homo sapiens
                           (IGHV3-33*01 (98.00%) -(IGHD)-IGHJ3*02) [8.8.13] (1-
                           120) -IGHG1*03 (CH1 (121-218), bisagra (219-233), CH2
                           (234-343), CH3 (344-448), CHS (449-450)) (121-450)],
                           (223-216')-disulfuro con la cadena ligera kappa (1'-216')
                           [V-KAPPA de Homo sapiens (IGKV3-11*01 (95.80%) -
                           IGKJ2*01) [6.3.11] (1'-109') -IGKC*01 (110'-216')]; dímero
                           (229-229'':232-232'')-bisdisulfuro
                           Heavy chain / Chaîne lourde / Cadena pesada
                           EVQLVESGGG VVQPGRSLRL SCAASGFTFS                  SYGMHWVRQA       PGKGLEWVAI        50
                           IWYDGSNKYY ADSVKGRFTI SRDNSKNTLY                  LQMNSLRAED       TAVYYCARLW       100
                           FGDLDAFDIW GQGTMVTVSS ASTKGPSVFP                  LAPSSKSTSG       GTAALGCLVK       150
                           DYFPEPVTVS WNSGALTSGV HTFPAVLQSS                  GLYSLSSVVT       VPSSSLGTQT       200
                           YICNVNHKPS NTKVDKRVEP KSCDKTHTCP                  PCPAPELLGG       PSVFLFPPKP       250
                           KDTLMISRTP EVTCVVVDVS HEDPEVKFNW                  YVDGVEVHNA       KTKPREEQYN       300
                           STYRVVSVLT VLHQDWLNGK EYKCKVSNKA                  LPAPIEKTIS       KAKGQPREPQ       350
                           VYTLPPSREE MTKNQVSLTC LVKGFYPSDI                  AVEWESNGQP       ENNYKTTPPV       400
                           LDSDGSFFLY SKLTVDKSRW QQGNVFSCSV                  MHEALHNHYT       QKSLSLSPGK       450

                           Light chain / Chaîne légère / Cadena ligera
                           EIVLTQSPAT LSLSPGERAI LSCRAGQSVS                  SYLVWYQQKP       GQAPRLLIYD 50
                           ASNRATGIPA RFSGSGSGTD FTLTISSLEP                  EDFAVYYCQQ       RSSWPPVYTF 100
                           GQGTKLEIKR TVAAPSVFIF PPSDEQLKSG                  TASVVCLLNN       FYPREAKVQW 150
                           KVDNALQSGN SQESVTEQDS KDSTYSLSST                  LTLSKADYEK       HKVYACEVTH 200
                           QGLSSPVTKS FNRGEC                                                             216

                           Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro
                           Intra-H (C23-C104) 22-96          147-203       264-324   370-428
                                                 22''-96'' 147''-203'' 264''-324'' 370''-428''
                           Intra-L (C23-C104) 23'-88'         136'-196'
                                                 23'''-88''' 136'''-196'''
                           Inter-H-L (h 5-CL 126) 223-216' 223''-216'''
                           Inter-H-H (h 11, h 14) 229-229'' 232-232''

                           N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación
                           H CH2 N84.4:
                           300, 300''

                           Other post-translational modifications / Autres modifications post-traductionnelles / Otras
                            modificaciones post-traduccionales
                           H CHS K2 C-terminal lysine clipping:
                           450, 450'




392
WHO Drug Information, Vol. 29, No. 3, 2015                             Recommended INN: List 74




 desfesoterodinum
 desfesoterodine                       2-{(1R)-3-[bis(propan-2-yl)amino]-1-phenylpropyl}-
                                       4-(hydroxymethyl)phenol

 desfésotérodine                       2-{(1R)-3-[bis(propan-2-yl)amino]-1-phénylpropyl}-
                                       4-(hydroxyméthyl)phenol

 desfesoterodina                       2-{(1R)-3-[bis(propan-2-il)amino]-1-fenilpropil}-
                                       4-(hidroximetil)fenol

                                       C22H31NO2



                                             OH H              CH3

                                                           N       CH3

                                                    H3 C       CH3

                                               OH

 deutetrabenazinum
                                                                   2
 deutetrabenazine                      rac-(3R,11bR)-9,10-di[( H3)methoxy]-3-(2-methylpropyl)-
                                       1,3,4,6,7,11b-hexahydro-2H-pyrido[2,1-a]isoquinolin-2-one
                                                                   2
 deutétrabénazine                      rac-(3R,11bR)-9,10-di[( H3)méthoxy]-3-(2-méthylpropyl)-
                                       1,3,4,6,7,11b-hexahydro-2H-pyrido[2,1-a]isoquinoléin-
                                       2-one
                                                                                 2
 deutetrabenazina                      rac-(3R,11bR)-3-(2-metilpropi)-9,10-di[( H3)metoxi]-
                                       1,3,4,6,7,11b-hexahidro-2H-pirido[2,1-a]isoquinolein-2-ona
                                                2
                                       C19H21( H6)NO3

                                        rac                    O
                                                                   H
                                                                           CH3

                                        2
                                                      H
                                         H3CO                            CH3
                                                               N

                                        2
                                         H3CO

 durvalumabum #
 durvalumab                            immunoglobulin G1-kappa, anti-[Homo sapiens CD274
                                       (programmed death ligand 1, PDL1, PD-L1, B7 homolog 1,
                                       B7H1)], Homo sapiens monoclonal antibody;
                                       gamma1 heavy chain (1-451) [Homo sapiens VH (IGHV3-
                                       7*01 (99.00%) -(IGHD)-IGHJ4*01) [8.8.14] (1-121) -
                                       IGHG1*03 (CH1 (122-219), hinge (220-234), CH2 (235-
                                       344) L1.3>F (238), L1.2>E (239), P116>S (335), CH3
                                       (345-449), CHS (450-451)) (122-451)], (224-215')-disulfide
                                       with kappa light chain (1'-215') [Homo sapiens V-KAPPA
                                       (IGKV3-20*01 (96.90%) -IGKJ1*01) [7.3.9] (1'-108') -
                                       IGKC*01 (109'-215')]; dimer (230-230'':233-233'')-
                                       bisdisulfide




                                                                                             393
Recommended INN: List 74               WHO Drug Information, Vol. 29, No. 3, 2015



 durvalumab                immunoglobuline G1-kappa, anti-[Homo sapiens CD274
                           (ligand 1 de mort programmée, PDL1, PD-L1, homologue
                           1 de B7, B7H1)],Homo sapiens anticorps monoclonal;
                           chaîne lourde gamma1 (1-451) [Homo sapiens VH
                           (IGHV3-7*01 (99.00%) -(IGHD)-IGHJ4*01) [8.8.14] (1-121)
                           -IGHG1*03 (CH1 (122-219), charnière (220-234), CH2
                           (235-344) L1.3>F (238), L1.2>E (239), P116>S (335), CH3
                           (345-449), CHS (450-451)) (122-451)], (224-215')-disulfure
                           avec la chaîne légère kappa (1'-215') [Homo sapiens
                           V-KAPPA (IGKV3-20*01 (96.90%) -IGKJ1*01) [7.3.9]
                           (1'-108') -IGKC*01 (109'-215')]; dimère (230-230'':233-
                           233'')-bisdisulfure

 durvalumab                inmunoglobulina G1-kappa, anti-[Homo sapiens CD274
                           (ligando 1 de muerte programada, PDL1, PD-L1,
                           homólogo 1 de B7, B7H1)], anticuerpo monoclonal de
                           Homo sapiens;
                           cadena pesada gamma1 (1-451) [Homo sapiens VH
                           (IGHV3-7*01 (99.00%) -(IGHD)-IGHJ4*01) [8.8.14] (1-121)
                           -IGHG1*03 (CH1 (122-219),bisagra (220-234), CH2 (235-
                           344) L1.3>F (238), L1.2>E (239), P116>S (335), CH3
                           (345-449), CHS (450-451)) (122-451)], (224-215')-disulfuro
                           con la cadena ligera kappa (1'-215') [Homo sapiens
                           V-KAPPA (IGKV3-20*01 (96.90%) -IGKJ1*01) [7.3.9]
                           (1'-108') -IGKC*01 (109'-215')]; dímero (230-230'':233-
                           233'')-bisdisulfuro


                           Heavy chain / Chaîne lourde / Cadena pesada
                           EVQLVESGGG LVQPGGSLRL SCAASGFTFS                  RYWMSWVRQA       PGKGLEWVAN        50
                           IKQDGSEKYY VDSVKGRFTI SRDNAKNSLY                  LQMNSLRAED       TAVYYCAREG       100
                           GWFGELAFDY WGQGTLVTVS SASTKGPSVF                  PLAPSSKSTS       GGTAALGCLV       150
                           KDYFPEPVTV SWNSGALTSG VHTFPAVLQS                  SGLYSLSSVV       TVPSSSLGTQ       200
                           TYICNVNHKP SNTKVDKRVE PKSCDKTHTC                  PPCPAPEFEG       GPSVFLFPPK       250
                           PKDTLMISRT PEVTCVVVDV SHEDPEVKFN                  WYVDGVEVHN       AKTKPREEQY       300
                           NSTYRVVSVL TVLHQDWLNG KEYKCKVSNK                  ALPASIEKTI       SKAKGQPREP       350
                           QVYTLPPSRE EMTKNQVSLT CLVKGFYPSD                  IAVEWESNGQ       PENNYKTTPP       400
                           VLDSDGSFFL YSKLTVDKSR WQQGNVFSCS                  VMHEALHNHY       TQKSLSLSPG       450
                           K                                                                                   451

                           Light chain / Chaîne légère / Cadena ligera
                           EIVLTQSPGT LSLSPGERAT LSCRASQRVS                  SSYLAWYQQK       PGQAPRLLIY 50
                           DASSRATGIP DRFSGSGSGT DFTLTISRLE                  PEDFAVYYCQ       QYGSLPWTFG 100
                           QGTKVEIKRT VAAPSVFIFP PSDEQLKSGT                  ASVVCLLNNF       YPREAKVQWK 150
                           VDNALQSGNS QESVTEQDSK DSTYSLSSTL                  TLSKADYEKH       KVYACEVTHQ 200
                           GLSSPVTKSF NRGEC                                                              215

                           Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disul
                           Intra-H (C23-C104) 22-96          148-204       265-325   371-429
                                                 22''-96'' 148''-204'' 265''-325'' 371''-429''
                           Intra-L (C23-C104) 23'-89'         135'-195'
                                                 23'''-89''' 135'''-195'''
                           Inter-H-L (h 5-CL 126) 224-215' 224''-215'''
                           Inter-H-H (h 11, h 14) 230-230'' 233-233''

                           N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación
                           H CH2 N84.4:
                           301, 301''



 elafibranorum
 elafibranor               2-(2,6-dimethyl-4-{3-[4-(methylsulfanyl)phenyl]-3-oxoprop-
                           1-en-1-yl}phenoxy)-2-methylpropanoic acid

 élafibranor               acide 2-(2,6-diméthyl-4-{3-[4-(méthylsulfanyl)phényl]-
                           3-oxoprop-1-én-1-yl}phénoxy)-2-méthylpropanoïque




394
WHO Drug Information, Vol. 29, No. 3, 2015                              Recommended INN: List 74




 elafibranor                           ácido 2-(2,6-dimetil-4-{3-[4-(metilsulfanil)fenil]-3-oxoprop-
                                       1-en-1-il}fenoxi)-2-metilpropanoico

                                       C22H24O4S

                                                                         CH3
                                                                                      CO2H
                                                           O                   O
                                                                                       CH3
                                                                                     CH3
                                                                               CH3
                                        H3 C
                                               S



 eleclazinum
 eleclazine                            4-[(pyrimidin-2-yl)methyl]-7-[4-(trifluoromethoxy)phenyl]-
                                       3,4-dihydro-1,4-benzoxazepin-5(2H)-one

 éléclazine                            4-[(pyrimidin-2-yl)méthyl)-7-[4-(trifluorométhoxy)phényl]-
                                       3,4-dihydro-1,4-benzoxazépin-5(2H)-one

 eleclazina                            4-[(pirimidin-2-il)metil)-7-[4-(trifluorometoxi)fenil]-
                                       3,4-dihidro-1,4-benzoxazepin-5(2H)-ona

                                       C21H16F3N3O3

                                                                    O

                                                                                N
                                                                         N
                                        F3C                         O
                                               O                                 N



 elgemtumabum #
 elgemtumab                            immunoglobulin G1-kappa, anti-[Homo sapiens ERBB3
                                       (receptor tyrosine-protein kinase erbB-3, HER3)], Homo
                                       sapiens monoclonal antibody;
                                       gamma1 heavy chain (1-447) [Homo sapiens VH (IGHV3-
                                       23*01 (94.90%) -(IGHD)-IGHJ4*01) [8.8.10] (1-117) -
                                       IGHG1*03 (CH1 (118-215), hinge (216-230), CH2 (231-
                                       340), CH3 (341-445), CHS (446-447)) (118-447)], (220-
                                       214')-disulfide with kappa light chain (1'-214') [Homo
                                       sapiens V-KAPPA (IGKV1-12*01 (94.70%) -IGKJ1*01)
                                       [6.3.9] (1'-107') -IGKC*01 (108'-214')]; dimer (226-
                                       226'':229-229'')-bisdisulfide

 elgemtumab                            immunoglobuline G1-kappa, anti-[Homo sapiens ERBB3
                                       (récepteur à activité tyrosine kinase erbB-3, HER3)], Homo
                                       sapiens anticorps monoclonal;
                                       chaîne lourde gamma1 (1-447) [Homo sapiens VH
                                       (IGHV3-23*01 (94.90%) -(IGHD)-IGHJ4*01) [8.8.10]
                                       (1-117) -IGHG1*03 (CH1 (118-215), charnière (216-230),
                                       CH2 (231-340), CH3 (341-445), CHS (446-447)) (118-
                                       447)], (220-214')-disulfure avec la chaîne légère kappa
                                       (1'-214') [Homo sapiens V-KAPPA (IGKV1-12*01 (94.70%)
                                       -IGKJ1*01) [6.3.9] (1'-107') -IGKC*01 (108'-214')]; dimère
                                       (226-226'':229-229'')-bisdisulfure




                                                                                                  395
Recommended INN: List 74                WHO Drug Information, Vol. 29, No. 3, 2015



 elgemtumab                inmunoglobulina G1-kappa, anti-[ERBB3 de Homo sapiens
                           (receptor tirosina-proteína kinasa erbB-3, HER3)],
                           anticuerpo monoclonal de Homo sapiens;
                           cadena pesada gamma1 (1-447) [Homo sapiens VH
                           (IGHV3-23*01 (94.90%) -(IGHD)-IGHJ4*01) [8.8.10]
                           (1-117) -IGHG1*03 (CH1 (118-215), bisagra (216-230),
                           CH2 (231-340), CH3 (341-445), CHS (446-447)) (118-
                           447)], (220-214')-disulfuro con la cadena ligera kappa
                           (1'-214') [Homo sapiens V-KAPPA (IGKV1-12*01 (94.70%)
                           -IGKJ1*01) [6.3.9] (1'-107') -IGKC*01 (108'-214')]; dímero
                           (226-226'':229-229'')-bisdisulfuro

                           Heavy chain / Chaîne lourde / Cadena pesada
                           EVQLLESGGG LVQPGGSLRL SCAASGFTFS                   SYAMSWVRQA      PGKGLEWVSA        50
                           INSQGKSTYY ADSVKGRFTI SRDNSKNTLY                   LQMNSLRAED      TAVYYCARWG       100
                           DEGFDIWGQG TLVTVSSAST KGPSVFPLAP                   SSKSTSGGTA      ALGCLVKDYF       150
                           PEPVTVSWNS GALTSGVHTF PAVLQSSGLY                   SLSSVVTVPS      SSLGTQTYIC       200
                           NVNHKPSNTK VDKRVEPKSC DKTHTCPPCP                   APELLGGPSV      FLFPPKPKDT       250
                           LMISRTPEVT CVVVDVSHED PEVKFNWYVD                   GVEVHNAKTK      PREEQYNSTY       300
                           RVVSVLTVLH QDWLNGKEYK CKVSNKALPA                   PIEKTISKAK      GQPREPQVYT       350
                           LPPSREEMTK NQVSLTCLVK GFYPSDIAVE                   WESNGQPENN      YKTTPPVLDS       400
                           DGSFFLYSKL TVDKSRWQQG NVFSCSVMHE                   ALHNHYTQKS      LSLSPGK          447

                           Light chain / Chaîne légère / Cadena ligera
                           DIQMTQSPSS LSASVGDRVT ITCRASQGIS                   NWLAWYQQKP      GKAPKLLIYG 50
                           ASSLQSGVPS RFSGSGSGTD FTLTISSLQP                   EDFATYYCQQ      YSSFPTTFGQ 100
                           GTKVEIKRTV AAPSVFIFPP SDEQLKSGTA                   SVVCLLNNFY      PREAKVQWKV 150
                           DNALQSGNSQ ESVTEQDSKD STYSLSSTLT                   LSKADYEKHK      VYACEVTHQG 200
                           LSSPVTKSFN RGEC                                                               214

                           Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro
                           Intra-H (C23-C104) 22-96          144-200 261-321         367-425
                                                 22''-96'' 144''-200'' 261''-321'' 367''-425''
                           Intra-L (C23-C104) 23'-88'         134'-194'
                                                 23'''-88''' 134'''-194'''
                           Inter-H-L (h 5-CL 126) 220-214' 220''-214'''
                           Inter-H-H (h 11, h 14) 226-226'' 229-229''

                           N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación
                           H CH2 N84.4:
                           297, 297''

                           Other post-translational modifications / Autres modifications post-traductionnelles / Otras
                           modificaciones post-traduccionales
                           H CHS K2 C-terminal lysine clipping:
                           447, 447'




 emeramidum
                            1    3
 emeramide                 N ,N -bis(2-sulfanylethyl)benzene-1,3-dicarboxamide
                            1    3
 éméramide                 N ,N -bis(2-sulfanyléthyl)benzène-1,3-dicarboxamide
                            1    3
 emeramida                 N ,N -bis(2-sulfaniletil)benceno-1,3-dicarboxamida

                           C12H16N2O2S2


                                            H                             H
                                            N                             N
                            HS                                                          SH
                                                 O                   O



 epetraborolum
 epetraborole              (3S)-3-(aminomethyl)-7-(3-hydroxypropoxy)-
                           2,1-benzoxaborol-1(3H)-ol

 épétraborole              (3S)-3-(aminométhyl)-7-(3-hydroxypropoxy)-
                           2,1-benzoxaborol-1(3H)-ol




396
WHO Drug Information, Vol. 29, No. 3, 2015                          Recommended INN: List 74


 epetraborol                           (3S)-3-(aminometil)-7-(3-hidroxipropoxi)-2,1-benzoxaborol-
                                       1(3H)-ol

                                       C11H16BNO4

                                        HO             O     OH
                                                            B
                                                                O
                                                                    NH2
                                                            H

 eprociclovirum
 eprociclovir                          2-amino-9-{[(1S,2R)-1,2-bis(hydroxymethyl)cyclopropyl]
                                       methyl}-1,9-dihydro-6H-purin-6-one

 éprociclovir                          2-amino-9-{[(1S,2R)-1,2-bis(hydroxyméthyl)cyclopropyl]
                                       méthyl}-1,9-dihydro-6H-purin-6-one

 eprociclovir                          2-amino-9-{[(1S,2R)-1,2-bis(hidroximetil)ciclopropil]metil}-
                                       1,9-dihidro-6H-purin-6-ona

                                       C11H15N5O3

                                                   O

                                                        N
                                              HN
                                                            H       OH
                                        H2N        N    N

                                                       HO

 eptacogum beta (activatum) #
 eptacog beta (activated)              recombinant DNA derived blood-coagulation factor VII
                                       (activated), extracted from transgenic rabbits’ milk:
                                       blood-coagulation factor VII (EC 3.4.21.21, proconvertin,
                                       serum prothrombin conversion accelerator), human factor
                                       VII light chain (135-262)-disulfide with human factor VII
                                       heavy chain

 eptacog bêta (activé)                 facteur VII de la coagulation sanguine (activé) à partir
                                       d'ADN recombinant, extrait du lait de lapins transgéniques:
                                       facteur VII de la coagulation sanguine (EC3.4.21.21,
                                       proconvertine, accélérateur de conversion de la
                                       prothrombine sérique), (135-262) disulfure entre la chaîne
                                       légère et la chaîne lourde du facteur VII humain,
                                       glycoforme beta

 eptacog beta (activado)               factor VII de la coagulación sanguínea (activado) a partir
                                       de ADN recombinante, extraído de leche de conejas
                                       transgénicas:
                                       factor VII de la coagulación sanguínea (EC 3.4.21.21,
                                       proconvertina, acelerador de conversión de la protrombina
                                       sérica), (135-262) disulfuro entre la cadena ligera y la
                                       cadena pesada del factor VII humano, glicoforma beta




                                                                                                397
Recommended INN: List 74                WHO Drug Information, Vol. 29, No. 3, 2015



                           Light chain / Chaîne légère / Cadena ligera
                           ANAFLEELRP GSLERECKEE QCSFEEAREI FKDAERTKLF WISYSDGDQC 50
                           ASSPCQNGGS CKDQLQSYIC FCLPAFEGRN CETHKDDQLI CVNENGGCEQ 100
                           YCSDHTGTKR SCRCHEGYSL LADGVSCTPT VEYPCGKIPI LEKRNASKPQ 150
                           GR                                                     152

                           Heavy chain / Chaîne lourde / Cadena pesada
                             IVGGKVCP KGECPWQVLL LVNGAQLCGG                   TLINTIWVVS       AAHCFDKIKN       200
                           WRNLIAVLGE HDLSEHDGDE QSRRVAQVII                   PSTYVPGTTN       HDIALLRLHQ       250
                           PVVLTDHVVP LCLPERTFSE RTLAFVRFSL                   VSGWGQLLDR       GATALELMVL       300
                           NVPRLMTQDC LQQSRKVGDS PNITEYMFCA                   GYSDGSKDSC       KGDSGGPHAT       350
                           HYRGTWYLTG IVSWGQGCAT VGHFGVYTRV                   SQYIEWLQKL       MRSEPRPGVL       400
                           LRAPFP                                                                               406

                           Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro
                           17-22      50-61     55-70     72-81      91-102      98-112
                           114-127 135-262 159-164 178-194 310-329 340-368

                           Modified residues / Résidus modifiés / Restos modificados
                                                                                               H NH2
                                  E          HO2C         H   NH2              D
                           6-7-14-16-19-20                                     63        HO2C
                             25-26-29-35                               (3R)-3-hydroxyAsp          CO2H
                            4-carboxyGlu   HO2C                CO2H
                                                                                            HO H

                           Glycosylation sites (S, N) / Sites de glycosylation (S, N) / Posiciones de glicosilación (S, N)
                           Ser-52 Ser-60 Asn-145 Asn-322



 etelcalcetidum
 etelcalcetide             N-acetyl-D-cysteinyl-D-alanyl-D-arginyl-D-arginyl-D-arginyl-
                           D-alanyl-D-argininamide disulfide with L-cystein

 ételcalcétide             disulfure entre le N-acétyl-D-cystéinyl-D-alanyl-D-arginyl-
                           D-arginyl-D-arginyl-D-alanyl-D-argininamide et la L-cystéine

 etelcalcetida             disulfuro entre el N-acetil-D-cisteinil-D-alanil-D-arginil-
                           D-arginil-D-arginil-D-alanil-D-argininamida y la L-cisteina

                                   H L-Cys OH
                           H3C
                                  C   D-Cys       D-Ala       D-Arg     D-Arg      D-Arg      D-Ala      D-Arg NH2
                              O


 evinacumabum #
 evinacumab                immunoglobulin G4-kappa, anti-[Homo sapiens ANGPTL3
                           (angiopoietin-like 3)], human monoclonal antibody;
                           gamma4 heavy chain (1-453) [Homo sapiens VH (IGHV3-
                           43*02 (92.90%) -(IGHD)-IGHJ3*02) [8.8.19](1-126) -
                           IGHG4*01 (CH1(127-224), hinge S10>P(234) (225-236),
                           CH2 (237-346), CH3(347-451),CHS (452-453)) (127-453)],
                           (140-214')-disulfide with kappa light chain (1’-214’) [Homo
                           sapiens (V-KAPPA (IGKV1-5*03 (98.90%) -IGKJ2*01)
                           [6.3.9] (1'-107') -IGKC*01 (108'-214')]; dimer (232-
                           232":235-235")-bisdisulfide

 évinacumab                immunoglobuline G4-kappa, anti-[Homo sapiens
                           ANGPTL3 (angiopoïétine-like 3)], anticorps monoclonal
                           humain;
                           chaîne lourde gamma4 (1-453) [Homo sapiens VH
                           (IGHV3-43*02 (92.90%) -(IGHD)-IGHJ3*02) [8.8.19]
                           (1-126) -IGHG4*01 (CH1 (127-224), charnière S10>P
                           (234) (225-236), CH2 (237-346), CH3 (347-451), CHS
                           (452-453)) (127-453)], (140-214')-disulfure avec la chaîne
                           légère kappa (1’-214’) [Homo sapiens (V-KAPPA (IGKV1-
                           5*03 (98.90%) -IGKJ2*01) [6.3.9] (1'-107') -IGKC*01 (108'-
                           214')]; dimère (232-232":235-235")-bisdisulfure




398
WHO Drug Information, Vol. 29, No. 3, 2015                                        Recommended INN: List 74




 evinacumab                            inmunoglobulina G4-kappa, anti-[ANGPTL3
                                       (angiopoyetina-like 3) de Homo sapiens], anticuerpo
                                       monoclonal humano;
                                       cadena pesada gamma4 (1-453) [VH de Homo sapiens
                                       (IGHV3-43*02 (92.90%) -(IGHD)-IGHJ3*02) [8.8.19]
                                       (1-126) -IGHG4*01 (CH1 (127-224), bisagra S10>P (234)
                                       (225-236), CH2 (237-346), CH3 (347-451), CHS (452-
                                       453)) (127-453)], (140-214')-disulfuro con la cadena ligera
                                       kappa (1’-214’) [Homo sapiens (V-KAPPA (IGKV1-5*03
                                       (98.90%) -IGKJ2*01) [6.3.9] (1'-107') -IGKC*01 (108'-
                                       214')]; dímero (232-232":235-235")-bisdisulfuro

                                       Heavy chain / Chaîne lourde / Cadena pesada
                                       EVQLVESGGG VIQPGGSLRL SCAASGFTFD                  DYAMNWVRQG       PGKGLEWVSA        50
                                       ISGDGGSTYY ADSVKGRFTI SRDNSKNSLY                  LQMNSLRAED       TAFFYCAKDL       100
                                       RNTIFGVVIP DAFDIWGQGT MVTVSSASTK                  GPSVFPLAPC       SRSTSESTAA       150
                                       LGCLVKDYFP EPVTVSWNSG ALTSGVHTFP                  AVLQSSGLYS       LSSVVTVPSS       200
                                       SLGTKTYTCN VDHKPSNTKV DKRVESKYGP                  PCPPCPAPEF       LGGPSVFLFP       250
                                       PKPKDTLMIS RTPEVTCVVV DVSQEDPEVQ                  FNWYVDGVEV       HNAKTKPREE       300
                                       QFNSTYRVVS VLTVLHQDWL NGKEYKCKVS                  NKGLPSSIEK       TISKAKGQPR       350
                                       EPQVYTLPPS QEEMTKNQVS LTCLVKGFYP                  SDIAVEWESN       GQPENNYKTT       400
                                       PPVLDSDGSF FLYSRLTVDK SRWQEGNVFS                  CSVMHEALHN       HYTQKSLSLS       450
                                       LGK                                                                                 453

                                       Light chain / Chaîne légère / Cadena ligera
                                       DIQMTQSPST LSASVGDRVT ITCRASQSIR                  SWLAWYQQKP       GKAPKLLIYK 50
                                       ASSLESGVPS RFSGSGSGTE FTLTISSLQP                  DDFATYYCQQ       YNSYSYTFGQ 100
                                       GTKLEIKRTV AAPSVFIFPP SDEQLKSGTA                  SVVCLLNNFY       PREAKVQWKV 150
                                       DNALQSGNSQ ESVTEQDSKD STYSLSSTLT                  LSKADYEKHK       VYACEVTHQG 200
                                       LSSPVTKSFN RGEC                                                               214

                                       Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro
                                       Intra-H (C23-C104) 22-96 153-209 267-327 373-431
                                         22''-96'' 153''-209'' 267''-327'' 373''-431''
                                       Intra-L (C23-C104) 23'-88' 134'-194'
                                         23'''-88''' 134'''-194'''
                                       Inter-H-L (CH1 10-CL 126) 140-214' 140''-214'''
                                       Inter-H-H (h 8, h 11) 232-232'' 235-235''

                                       N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación
                                       H CH2 N84.4:
                                       303, 303''



                     18
 flutafuranolum ( F)
               18                             18
 flutafuranol ( F)                     2-{2-[ F]fluoro-6-(methylamino)pyridin-3-yl}-1-benzofuran-
                                       5-ol
              18                              18
 flutafuranol ( F)                     2-{2-[ F]fluoro-6-(méthylamino)pyridin-3-yl}-1-benzofuran-
                                       5-ol
              18                              18
 flutafuranol ( F)                     2-{2-[ F]fluoro-6-(metilamino)piridin-3-il}-1-benzofuran-5-ol
                                                   18
                                       C14H11 FN2O2

                                                             O
                                                                                      NH
                                        HO                                    N        CH3
                                                                   18
                                                                      F



 follitropinum delta #
 follitropin delta                     recombinant DNA derived heterodimer of human
                                       glycoprotein hormones alpha chain and follitropin subunit
                                       beta (FSH-beta) follicle-stimulating hormone, expressed in
                                       PER.C6 cells, glycoform delta




                                                                                                                               399
Recommended INN: List 74                WHO Drug Information, Vol. 29, No. 3, 2015



 follitropine delta        hétérodimère constitué de la chaîne alpha des hormones
                           glycoprotéiques et de la sous-unité bêta de la follitropine
                           (HFS-bêta) humaines, hormone folliculostimulante,
                           exprimée dans les cellules PER.C6 à partir d'ADN
                           recombinant, forme glycosylée delta

 folitropina delta         heterodímero constituido por la cadena alfa de las
                           hormonas glicoproteícas y la subunidad beta de la
                           folitropina (HFS-beta) humanas, hormona estimulante del
                           folículo, expresada en células PER.C6 a partir de ADN
                           recombinante, forma glicosilada delta
                           alpha chain / chaîne alpha / cadena alfa
                           APDVQDCPEC TLQENPFFSQ PGAPILQCMG CCFSRAYPTP LRSKKTMLVQ 50
                           KNVTSESTCC VAKSYNRVTV MGGFKVENHT ACHCSTCYYH KS         92

                           beta chain / chaîne bêta / cadena beta
                           NSCELTNITI AIEKEECRFC ISINTTWCAG YCYTRDLVYK DPARPKIQKT 50'
                           CTFKELVYET VRVPGCAHHA DSLYTYPVAT QCHCGKCDSD STDCTVRGLG 100'
                           PSYCSFGEMK E                                           111'

                           Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro
                           7-31 10-60 28-82           32-84 59-87
                           3'-51' 17'-66' 20'-104' 28'-82' 32'-84' 87'-94'

                           Glycosylation sites (N) / Sites de glycosylation (N) / Posiciones de glicosilación (N)
                           Asn-52 Asn-78 Asn-7' Asn-24'



 gepotidacinum
 gepotidacin               (2R)-2-[(4-{[(3,4-dihydro-2H-pyrano[2,3-c]pyridin-
                           6-yl)methyl]amino}piperidin-1-yl)methyl]-1,2-dihydro-
                           3H,8H-2a,5,8a-triazaacenaphthylene-3,8-dione

 gépotidacine              (2R)-2-[(4-{[(3,4-dihydro-2H-pyrano[2,3-c]pyridin-
                           6-yl)méthyl]amino}pipéridin-1-yl)méthyl]-1,2-dihydro-
                           3H,8H-2a,5,8a-triazaacénaphthylène-3,8-dione

 gepotidacina              (2R)-2-[(4-{[(3,4-dihidro-2H-pirano[2,3-c]piridin-
                           6-il)metil]amino}piperidin-1-il)metil]-1,2-dihidro-
                           3H,8H-2a,5,8a-triazaacenaftileno-3,8-diona

                           C24H28N6O3
                                                                              O
                                                                                            N
                                                                                  N
                                                                     N
                                                                          H            N
                                                       N
                                                       H                                   O
                                             N
                               O



 gilteritinibum
 gilteritinib              6-ethyl-3-{3-methoxy-4-[4-(4-methylpiperazin-
                           1-yl)piperidin-1-yl]anilino}-5-[(oxan-4-yl)amino]pyrazine-
                           2-carboxamide

 giltéritinib              6-éthyl-3-{3-méthoxy-4-[4-(4-méthylpipérazin-
                           1-yl)pipéridin-1-yl]anilino}-5-[(oxan-4-yl)amino]pyrazine-
                           2-carboxamide




400
WHO Drug Information, Vol. 29, No. 3, 2015                            Recommended INN: List 74


 gilteritinib                          6-etil-3-{4-[4-(4-metilpiperazin-1-il)piperidin-1-il]-
                                       3-metoxianilino}-5-[(oxan-4-il)amino]pirazina-
                                       2-carboxamida

                                       C29H44N8O3

                                                 H2 N         O
                                                                  H
                                                                  N       OCH3
                                                     N
                                        H3C                   N
                                                                          N
                                                         NH
                                                                                      N
                                             O                                              N
                                                                                                CH3

 indimilastum
 indimilast                            N-{cis-4-[1-(4'-{[(3R,5S)-3,5-dimethylpiperazin-
                                       1-yl]methyl}[1,1'-biphenyl]-3-yl)-6-fluoro-2,4-dioxo-
                                       1,4-dihydropyrido[2,3-d]pyrimidin-3(2H)-yl]cyclohexyl}-
                                       2-methyl-1,3-thiazole-4-carboxamide

 indimilast                            N-{cis-4-[1-(4'-{[(3R,5S)-3,5-diméthylpipérazin-
                                       1-yl]méthyl}[1,1'-biphényl]-3-yl)-6-fluoro-2,4-dioxo-
                                       1,4-dihydropyrido[2,3-d]pyrimidin-3(2H)-yl]cyclohexyl}-
                                       2-méthyl-1,3-thiazole-4-carboxamide

 indimilast                            N-{cis-4-[1-(4'-{[(3R,5S)-3,5-dimetilpiperazin-1-il]metil}[1,1'-
                                       bifenil]-3-il)-6-fluoro-2,4-dioxo-1,4-dihidropirido[2,3-
                                       d]pirimidin-3(2H)-il]ciclohexil}-2-metil-1,3-tiazol-
                                       4-carboxamida

                                       C37H40FN7O3S
                                                                                  CH3
                                                                          N           H
                                                                                 NH

                                                                      H3C     H

                                                 N       N        O               S
                                                                      H                   CH3
                                                              N       N           N
                                        F
                                                              H       H
                                                         O                O

 indusatumabum #
 indusatumab                           immunoglobulin G1-kappa, anti-[Homo sapiens GUCY2C
                                       (guanylate cyclase 2C, guanylyl cyclase C, GCC,
                                       guanylate cyclase C, GC-C, heat-stable enterotoxin
                                       receptor, hSTAR, intestinal guanylate cyclase)], Homo
                                       sapiens monoclonal antibody;
                                       gamma1 heavy chain (1-449) [Homo sapiens VH (IGHV4-
                                       34*01 (94.80%) -(IGHD)-IGHJ1*01) [8.7.13] (1-119)-
                                       IGHG1*01 (CH1 (120-217), hinge (218-232), CH2 (233-
                                       342), CH3 (343-447), CHS (448-449)) (120-449)], (222-
                                       214')-disulfide with kappa light chain (1'-214') [Homo
                                       sapiens V-KAPPA (IGKV3-15*01 (95.80%) -IGKJ1*01
                                       K123>N (103) [6.3.9] (1'-107') -IGKC*01 (108'-214')]; dimer
                                       (228-228'':231-231'')-bisdisulfide




                                                                                                      401
Recommended INN: List 74                   WHO Drug Information, Vol. 29, No. 3, 2015


 indusatumab                 immunoglobuline G1-kappa, anti-[Homo sapiens GUCY2C
                             (guanylate cyclase 2C, guanylyl cyclase C, GCC, guanylate cyclase
                             C, GC-C, récepteur d’entérotoxine résistante à la chaleur, hSTAR,
                             guanylate cyclase intestinale)], Homo sapiens anticorps
                             monoclonal;
                             chaîne lourde gamma1 (1-449) [Homo sapiens VH (IGHV4-34*01
                             (94.80%) -(IGHD)-IGHJ1*01) [8.7.13]
                             (1-119)-IGHG1*01 (CH1 (120-217), charnière (218-232), CH2 (233-
                             342), CH3 (343-447), CHS (448-449)) (120-449)], (222-214')-
                             disulfure avec la chaîne légère kappa
                             (1'-214') [Homo sapiens V-KAPPA (IGKV3-15*01 (95.80%) -
                             IGKJ1*01 K123>N (103) [6.3.9](1'-107') -IGKC*01 (108'-214')];
                             dimère (228-228'':231-231'')-bisdisulfure

 indusatumab                 inmunoglobulina G1-kappa, anti-[GUCY2C de Homo sapiens
                             (guanilato ciclasa 2C, guanilil ciclasa C, GCC, guanilato ciclasa C,
                             GC-C, receptor de enterotoxina resistente al calor, hSTAR,
                             guanilato ciclasa intestinal)], anticuerpo monoclona de Homo
                             sapiens;
                             cadena pesada gamma1 (1-449) [VH de Homo sapiens (IGHV4-
                             34*01 (94.80%) -(IGHD)-IGHJ1*01) [8.7.13]
                             (1-119) -IGHG1*01 (CH1 (120-217), bisagra (218-232), CH2 (233-
                             342), CH3 (343-447), CHS (448-449)) (120-449)], (222-214')-
                             disulfuro con la cadena ligera kappa
                             (1'-214') [V-KAPPA de Homo sapiens (IGKV3-15*01 (95.80%) -
                             IGKJ1*01 K123>N (103) [6.3.9] (1'-107') -IGKC*01 (108'-214')];
                             dímero (228-228'':231-231'')-bisdisulfuro

                             Heavy chain / Chaîne lourde / Cadena pesada
                             QVQLQQWGAG LLKPSETLSL TCAVFGGSFS                  GYYWSWIRQP       PGKGLEWIGE        50
                             INHRGNTNDN PSLKSRVTIS VDTSKNQFAL                  KLSSVTAADT       AVYYCARERG       100
                             YTYGNFDHWG QGTLVTVSSA STKGPSVFPL                  APSSKSTSGG       TAALGCLVKD       150
                             YFPEPVTVSW NSGALTSGVH TFPAVLQSSG                  LYSLSSVVTV       PSSSLGTQTY       200
                             ICNVNHKPSN TKVDKKVEPK SCDKTHTCPP                  CPAPELLGGP       SVFLFPPKPK       250
                             DTLMISRTPE VTCVVVDVSH EDPEVKFNWY                  VDGVEVHNAK       TKPREEQYNS       300
                             TYRVVSVLTV LHQDWLNGKE YKCKVSNKAL                  PAPIEKTISK       AKGQPREPQV       350
                             YTLPPSRDEL TKNQVSLTCL VKGFYPSDIA                  VEWESNGQPE       NNYKTTPPVL       400
                             DSDGSFFLYS KLTVDKSRWQ QGNVFSCSVM                  HEALHNHYTQ       KSLSLSPGK        449

                             Light chain / Chaîne légère / Cadena ligera
                             EIVMTQSPAT LSVSPGERAT LSCRASQSVS                  RNLAWYQQKP       GQAPRLLIYG 50
                             ASTRATGIPA RFSGSGSGTE FTLTIGSLQS                  EDFAVYYCQQ       YKTWPRTFGQ 100
                             GTNVEIKRTV AAPSVFIFPP SDEQLKSGTA                  SVVCLLNNFY       PREAKVQWKV 150
                             DNALQSGNSQ ESVTEQDSKD STYSLSSTLT                  LSKADYEKHK       VYACEVTHQG 200
                             LSSPVTKSFN RGEC                                                               214

                             Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro
                             Intra-H (C23-C104) 22-95          146-202 263-323        369-427
                                                   22''-95'' 146''-202'' 263''-323'' 369''-427''
                             Intra-L (C23-C104) 23'-88'         134'-194'
                                                   23'''-88''' 134'''-194'''
                             Inter-H-L (h 5-CL 126) 222-214' 222''-214'''
                             Inter-H-H (h 11, h 14) 228-228'' 231-231''

                             N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación
                             H CH2 N84.4:
                             299, 299''

 indusatumabum vedotinum #
 indusatumab vedotin         immunoglobulin G1-kappa, anti-[Homo sapiens GUCY2C
                             (guanylate cyclase 2C, guanylyl cyclase C, GCC, guanylate cyclase
                             C, GC-C, heat-stable enterotoxin receptor, hSTAR, intestinal
                             guanylate cyclase)], Homo sapiens monoclonal antibody;
                             gamma1 heavy chain (1-449) [Homo sapiens VH (IGHV4-34*01
                             (94.80%) -(IGHD)-IGHJ1*01) [8.7.13] (1-119)-IGHG1*01 (CH1
                             (120-217), hinge (218-232), CH2 (233-342), CH3 (343-447), CHS
                             (448-449)) (120-449)], (222-214')-disulfide with kappa light chain
                             (1'-214') [Homo sapiens V-KAPPA (IGKV3-15*01 (95.80%) -
                             IGKJ1*01 K123>N (103) [6.3.9] (1'-107') -IGKC*01 (108'-214')];
                             dimer (228-228'':231-231'')-bisdisulfide; conjugated, on an average
                             of 3 to 4 cysteinyl, to monomethylauristatin E (MMAE), via a
                             cleavable maleimidocaproyl-valyl-citrullinyl-
                             p-aminobenzyloxycarbonyl (mc-val-cit-PABC) type linker
                             For the vedotin part, please refer to the document “INN for
                             pharmaceutical substances: Names for radicals, groups and
                             others”*.




402
WHO Drug Information, Vol. 29, No. 3, 2015                                           Recommended INN: List 74




 indusatumab védotine                  immunoglobuline G1-kappa, anti-[Homo sapiens GUCY2C
                                       (guanylate cyclase 2C, guanylyl cyclase C, GCC, guanylate
                                       cyclase C, GC-C, récepteur d’entérotoxine résistante à la
                                       chaleur, hSTAR, guanylate cyclase intestinale)], Homo sapiens
                                       anticorps monoclonal;
                                       chaîne lourde gamma1 (1-449) [Homo sapiens VH (IGHV4-
                                       34*01 (94.80%) -(IGHD)-IGHJ1*01) [8.7.13] (1-119)-IGHG1*01
                                       (CH1 (120-217), charnière (218-232), CH2 (233-342), CH3
                                       (343-447), CHS (448-449)) (120-449)], (222-214')-disulfure
                                       avec la chaîne légère kappa (1'-214') [Homo sapiens V-KAPPA
                                       (IGKV3-15*01 (95.80%) -IGKJ1*01 K123>N (103) [6.3.9](1'-
                                       107') -IGKC*01 (108'-214')]; dimère (228-228'':231-231'')-
                                       bisdisulfure; conjugué, sur 3 à 4 cystéinyl en moyenne, au
                                       monométhylauristatine E (MMAE), via un linker clivable de
                                       type maléimidocaproyl-valyl-citrullinyl-
                                       p-aminobenzyloxycarbonyl (mc-val-cit-PABC)
                                       Pour la partie védotine, veuillez-vous référer au document “INN
                                       for pharmaceutical substances: Names for radicals, groups
                                       and others”*.

 indusatumab vedotina                  inmunoglobulina G1-kappa, anti-[GUCY2C de Homo sapiens
                                       (guailato ciclasa 2C, guanilil ciclasa C, GCC, guanilato ciclasa
                                       C, GC-C, receptor de enterotoxina resistente al calor, hSTAR,
                                       guanilato cyclase intestinale)], Homo sapiens anticuerpo
                                       monoclonal;
                                       cadena pesada gamma1 (1-449) [Homo sapiens VH (IGHV4-
                                       34*01 (94.80%) -(IGHD)-IGHJ1*01) [8.7.13] (1-119) -
                                       IGHG1*01 (CH1 (120-217), bisagra (218-232), CH2 (233-342),
                                       CH3 (343-447), CHS (448-449)) (120-449)], (222-214')-
                                       disulfuro con la cadena ligera kappa (1'-214') [Homo sapiens
                                       V-KAPPA (IGKV3-15*01 (95.80%) -IGKJ1*01 K123>N (103)
                                       [6.3.9] (1'-107') -IGKC*01 (108'-214')]; dímero (228-228'':231-
                                       231'')-bisdisulfuro; conjugada, en una media de 3 a 4 cisteinil,
                                       con monometilauristatina E (MMAE), mediante un conector
                                       escindible de tipo maleimidocaproil-valil-citrulinil-
                                       p-aminobenciloxicarbonil (mc-val-cit-PABC)
                                       La fracción vedotina, pueden encontrarla en el documento
                                       “INN for pharmaceutical substances: Names for radicals,
                                       groups and others”*.

                                       Heavy chain / Chaîne lourde / Cadena pesada
                                       QVQLQQWGAG LLKPSETLSL TCAVFGGSFS                  GYYWSWIRQP       PGKGLEWIGE        50
                                       INHRGNTNDN PSLKSRVTIS VDTSKNQFAL                  KLSSVTAADT       AVYYCARERG       100
                                       YTYGNFDHWG QGTLVTVSSA STKGPSVFPL                  APSSKSTSGG       TAALGCLVKD       150
                                       YFPEPVTVSW NSGALTSGVH TFPAVLQSSG                  LYSLSSVVTV       PSSSLGTQTY       200
                                       ICNVNHKPSN TKVDKKVEPK SCDKTHTCPP                  CPAPELLGGP       SVFLFPPKPK       250
                                       DTLMISRTPE VTCVVVDVSH EDPEVKFNWY                  VDGVEVHNAK       TKPREEQYNS       300
                                       TYRVVSVLTV LHQDWLNGKE YKCKVSNKAL                  PAPIEKTISK       AKGQPREPQV       350
                                       YTLPPSRDEL TKNQVSLTCL VKGFYPSDIA                  VEWESNGQPE       NNYKTTPPVL       400
                                       DSDGSFFLYS KLTVDKSRWQ QGNVFSCSVM                  HEALHNHYTQ       KSLSLSPGK        449

                                       Light chain / Chaîne légère / Cadena ligera
                                       EIVMTQSPAT LSVSPGERAT LSCRASQSVS                  RNLAWYQQKP       GQAPRLLIYG 50
                                       ASTRATGIPA RFSGSGSGTE FTLTIGSLQS                  EDFAVYYCQQ       YKTWPRTFGQ 100
                                       GTNVEIKRTV AAPSVFIFPP SDEQLKSGTA                  SVVCLLNNFY       PREAKVQWKV 150
                                       DNALQSGNSQ ESVTEQDSKD STYSLSSTLT                  LSKADYEKHK       VYACEVTHQG 200
                                       LSSPVTKSFN RGEC                                                               214

                                       Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro
                                       Intra-H (C23-C104) 22-95          146-202       263-323   369-427
                                                             22''-95'' 146''-202'' 263''-323'' 369''-427''
                                       Intra-L (C23-C104) 23'-88'        134'-194'
                                                             23'''-88''' 134'''-194'''
                                       Inter-H-L* (h 5-CL 126) 222-214' 222''-214'''
                                       Inter-H-H* (h 11, h 14) 228-228'' 231-231''
                                       *Two or three of the inter-chain disulfide bridges are not present, an average of 3 to
                                       4 cysteinyl being conjugated each via a thioether bond to a drug linker.
                                       *Deux ou trois des ponts disulfures inter-chaînes ne sont pas présents, 3 à 4 cystéinyl
                                       en moyenne étant chacun conjugué via une liaison thioéther à un linker-principe actif.
                                       *Faltan dos o tres puentes disulfuro inter-catenarios, una media de 3 a 4 cisteinil está
                                       conjugada a conectores de principio activo.

                                       N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación
                                       H CH2 N84.4:
                                       299, 299''




                                                                                                                                         403
Recommended INN: List 74            WHO Drug Information, Vol. 29, No. 3, 2015


 infigratinibum
 infigratinib              N'-(2,6-dichloro-3,5-dimethoxyphenyl)-N-{6-[4-(4-
                           ethylpiperazin-1-yl)anilino]pyrimidin-4-yl}-N-methylurea

 infigratinib              N'-(2,6-dichloro-3,5-diméthoxyphényl)-N-{6-[4-(4-
                           éthylpipérazin-1-yl)anilino]pyrimidin-4-yl}-N-méthylurée

 infigratinib              N'-(2,6-dicloro-3,5-dimetoxifenil)-N-{6-[4-(4-etilpiperazin-
                           1-il)anilino]pirimidin-4-il}-N-metilurea

                           C26H31Cl2N7O3

                            H3C     N                                            OCH3
                                          N                                 Cl
                                                           N    N       O

                                                       N            N        N          OCH3
                                                       H                     H
                                                                    CH3          Cl


 isatuximabum #
 isatuximab                immunoglobulin G1-kappa, anti-[Homo sapiens CD38
                           (ADP-ribosyl cyclase 1, cyclic ADP-ribose hydrolase 1,
                           cADPr hydrolase 1, T10)], chimeric monoclonal antibody;
                           gamma1 heavy chain (1-450) [Mus musculus VH (IGHV1-
                           7*01 (80.60%) -(IGHD)-IGHJ4*01) [8.8.13] (1-120) -Homo
                           sapiens IGHG1*01 (CH1 (121-218), hinge (219-233), CH2
                           (234-343), CH3 (344-448), CHS (449-450)) (121-450)],
                           (223-214')-disulfide with kappa light chain (1'-214') [Mus
                           musculus V-KAPPA (IGKV6-17*01 (89.50%) -IGKJ2*01)
                           [6.3.9] (1'-107') -Homo sapiens IGKC*01 (108'-214')];
                           dimer (229-229'':232-232'')-bisdisulfide

 isatuximab                immunoglobuline G1-kappa, anti-[Homo sapiens CD38
                           (ADP-ribosyl cyclase 1, ADP-ribose cyclique hydrolase 1,
                           cADPr hydrolase 1, T10)], anticorps monoclonal
                           chimérique;
                           chaîne lourde gamma1 (1-450) [Mus musculus VH
                           (IGHV1-7*01 (80.60%) -(IGHD)-IGHJ4*01) [8.8.13] (1-120)
                           -Homo sapiens IGHG1*01 (CH1 (121-218), charnière (219-
                           233), CH2 (234-343), CH3 (344-448), CHS (449-450))
                           (121-450)], (223-214')-disulfure avec la chaîne légère
                           kappa (1'-214') [Mus musculus V-KAPPA (IGKV6-17*01
                           (89.50%) -IGKJ2*01) [6.3.9] (1'-107') -Homo sapiens
                           IGKC*01 (108'-214')]; dimère (229-229'':232-232'')-
                           bisdisulfure

 isatuximab                inmunoglobulina G1-kappa, anti-[CD38 de Homo sapiens
                           (ADP-ribosil ciclasa 1, hidrolasa 1 de ADP-ribosa cíclica,
                           cADPr hidrolasa 1, T10)], anticuerpo monoclonal
                           quimérico;
                           cadena pesada gamma1 (1-450) [Mus musculus VH
                           (IGHV1-7*01 (80.60%) -(IGHD)-IGHJ4*01) [8.8.13] (1-120)
                           -Homo sapiens IGHG1*01 (CH1 (121-218), bisagra (219-
                           233), CH2 (234-343), CH3 (344-448), CHS (449-450))
                           (121-450)], (223-214')-disulfuro con la cadena ligera kappa
                           (1'-214') [Mus musculus V-KAPPA (IGKV6-17*01 (89.50%)
                           -IGKJ2*01) [6.3.9] (1'-107') -Homo sapiens IGKC*01 (108'-
                           214')]; dímero (229-229'':232-232'')-bisdisulfuro




404
WHO Drug Information, Vol. 29, No. 3, 2015                                        Recommended INN: List 74



                                       Heavy chain / Chaîne lourde / Cadena pesada
                                       QVQLVQSGAE VAKPGTSVKL SCKASGYTFT                  DYWMQWVKQR       PGQGLEWIGT        50
                                       IYPGDGDTGY AQKFQGKATL TADKSSKTVY                  MHLSSLASED       SAVYYCARGD       100
                                       YYGSNSLDYW GQGTSVTVSS ASTKGPSVFP                  LAPSSKSTSG       GTAALGCLVK       150
                                       DYFPEPVTVS WNSGALTSGV HTFPAVLQSS                  GLYSLSSVVT       VPSSSLGTQT       200
                                       YICNVNHKPS NTKVDKKVEP KSCDKTHTCP                  PCPAPELLGG       PSVFLFPPKP       250
                                       KDTLMISRTP EVTCVVVDVS HEDPEVKFNW                  YVDGVEVHNA       KTKPREEQYN       300
                                       STYRVVSVLT VLHQDWLNGK EYKCKVSNKA                  LPAPIEKTIS       KAKGQPREPQ       350
                                       VYTLPPSRDE LTKNQVSLTC LVKGFYPSDI                  AVEWESNGQP       ENNYKTTPPV       400
                                       LDSDGSFFLY SKLTVDKSRW QQGNVFSCSV                  MHEALHNHYT       QKSLSLSPGK       450

                                       Light chain / Chaîne légère / Cadena ligera
                                       DIVMTQSHLS MSTSLGDPVS ITCKASQDVS                  TVVAWYQQKP       GQSPRRLIYS 50
                                       ASYRYIGVPD RFTGSGAGTD FTFTISSVQA                  EDLAVYYCQQ       HYSPPYTFGG 100
                                       GTKLEIKRTV AAPSVFIFPP SDEQLKSGTA                  SVVCLLNNFY       PREAKVQWKV 150
                                       DNALQSGNSQ ESVTEQDSKD STYSLSSTLT                  LSKADYEKHK       VYACEVTHQG 200
                                       LSSPVTKSFN RGEC                                                               214

                                       Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro
                                       Intra-H (C23-C104) 22-96 147-203 264-324 370-428
                                         22''-96'' 147''-203'' 264''-324'' 370''-428''
                                       Intra-L (C23-C104) 23'-88' 134'-194'
                                         23'''-88''' 134'''-194'''
                                       Inter-H-L (h 5-CL 126) 223-214' 223''-214'''
                                       Inter-H-H (h 11, h 14) 229-229'' 232-232''

                                       N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación
                                       H CH2 N84.4:
                                       300, 300''


 lanopepdenum
 lanopepden                            N-[(2R)-2-(cyclopentylmethyl)-3-(2-{5-fluoro-6-[(9aS)-
                                       hexahydropyrazino[2,1-c][1,4]oxazin-8(1H)-yl]-
                                       2-methylpyrimidin-4-yl}hydrazin-1-yl)-3-oxopropyl]-
                                       N-hydroxyformamide

 lanopepdène                           N-[(2R)-2-(cyclopentylméthyl)-3-(2-{5-fluoro-6-[(9aS)-
                                       hexahydropyrazino[2,1-c][1,4]oxazin-8(1H)-yl]-
                                       2-méthylpyrimidin-4-yl}hydrazin-1-yl)-3-oxopropyl]-
                                       N-hydroxyformamide

 lanopepdén                            N-[(2R)-2-(ciclopentilmetil)-3-(2-{5-fluoro-6-[(9aS)-
                                       hexahidropirazino[2,1-c][1,4]oxazin-8(1H)-il]-
                                       2-metilpirimidin-4-il}hidrazin-1-il)-3-oxopropil]-
                                       N-hidroxiformamida

                                       C22H34FN7O4

                                                                                                 O
                                                                                       H
                                        O                  O                  F                  N
                                                                    H
                                                                    N                  N
                                             N                 N
                                                               H
                                             OH          H               N         N

                                                                              CH3


 lascufloxacinum
 lascufloxacin                         7-{(3S,4S)-3-[(cyclopropylamino)methyl]-4-fluoropyrrolidin-
                                       1-yl}-6-fluoro-1-(2-fluoroethyl)-8-methoxy-4-oxo-
                                       1,4-dihydroquinoline-3-carboxylic acid

 lascufloxacine                        acide 7-{(3S,4S)-3-[(cyclopropylamino)méthyl]-
                                       4-fluoropyrrolidin-1-yl}-6-fluoro-1-(2-fluoroéthyl)-8-méthoxy-
                                       4-oxo-1,4-dihydroquinoléine-3-carboxylique




                                                                                                                                 405
Recommended INN: List 74              WHO Drug Information, Vol. 29, No. 3, 2015




 lascufloxacino            ácido 7-{(3S,4S)-3-[(ciclopropilamino)metil]-
                           4-fluoropirrolidin-1-il}-6-fluoro-1-(2-fluoroetil)-8-metoxi-
                           4-oxo-1,4-dihidroquinoleina-3-carboxílico

                           C21H24F3N3O4

                                            F
                                        H
                                                     OCH3             F
                                  N
                                  H H           N            N


                                                F                     CO2H
                                                             O




 lavamilastum
 lavamilast                4-[(3,5-dichloropyridin-4-yl)amino]-7-methoxy-
                           8-{[6-(morpholin-4-yl)hexyl]oxy}quinolin-2(1H)-one

 lavamilast                4-[(3,5-dichloropyridin-4-yl)amino]-7-méthoxy-
                           8-{[6-(morpholin-4-yl)hexyl]oxy}quinoléin-2(1H)-one

 lavamilast                4-[(3,5-dicloropiridin-4-il)amino]-7-metoxi-8-{[6-(morfolin-
                           4-il)hexil]oxi}quinolein-2(1H)-ona

                           C25H30Cl2N4O4

                                                                      O
                                                                             Cl
                                                                 HN                    N
                                                         O
                                  N                                           N
                                                                              H
                            O                                                     Cl
                                                     H3CO




 lilotomabum #
 lilotomab                 immunoglobulin G1-kappa, anti-[Homo sapiens
                           CD37(TSPAN26, tetraspanin-26)], Mus musculus
                           monoclonal antibody;
                           gamma1 heavy chain (1-443) [Mus musculus VH
                           (IGHV1S135*01 (96.90%) -(IGHD)-IGHJ4*01) [8.8.12]
                           (1-119) -IGHG1*01 (CH1 E84>Q (177), P95>T (193),
                           R96>W (194) (120-216), hinge (217-229), CH2 (230-336),
                           CH3 N84.2>D (395), N84.4>D (397) (337-441), CHS (442-
                           443)) (120-443)], (221-214')-disulfide with kappa light chain
                           (1'-214') [Mus musculus V-KAPPA (IGKV6-25*01 (93.70%)
                           -IGKJ4*01) [6.3.9] (1'-107') -IGKC*01 (108'-214')]; dimer
                           (223-223'':226-226'':228-228'')-trisdisulfide




406
WHO Drug Information, Vol. 29, No. 3, 2015                                         Recommended INN: List 74


 lilotomab                             immunoglobuline G1-kappa, anti-[Homo sapiens CD37
                                       (TSPAN26, tétraspanine-26)], Mus musculus anticorps
                                       monoclonal;
                                       chaîne lourde gamma1 (1-443) [Mus musculus VH
                                       (IGHV1S135*01 (96.90%) -(IGHD)-IGHJ4*01) [8.8.12]
                                       (1-119) -IGHG1*01 (CH1 E84>Q (177), P95>T (193),
                                       R96>W (194) (120-216), charnière (217-229), CH2 (230-
                                       336), CH3 N84.2>D (395), N84.4>D (397) (337-441), CHS
                                       (442-443)) (120-443)], (221-214')-disulfure avec la chaîne
                                       légère kappa (1'-214') [Mus musculus V-KAPPA (IGKV6-
                                       25*01 (93.70%) -IGKJ4*01) [6.3.9] (1'-107') -IGKC*01
                                       (108'-214')]; dimère (223-223'':226-226'':228-228'')-
                                       trisdisulfure

 lilotomab                             inmunoglobulina G1-kappa, anti-[CD37 de Homo sapiens
                                       (TSPAN26, tetraspanina-26)], anticuerpo monoclonal de
                                       Mus musculus;
                                       cadena pesada gamma1 (1-443) [VH de Mus musculus
                                       (IGHV1S135*01 (96.90%) -(IGHD)-IGHJ4*01) [8.8.12]
                                       (1-119) -IGHG1*01 (CH1 E84>Q (177), P95>T (193),
                                       R96>W (194) (120-216), bisagra (217-229), CH2 (230-
                                       336), CH3 N84.2>D (395), N84.4>D (397) (337-441), CHS
                                       (442-443)) (120-443)], (221-214')-disulfuro con la cadena
                                       ligera kappa (1'-214') [Mus musculus V-KAPPA (IGKV6-
                                       25*01 (93.70%) -IGKJ4*01) [6.3.9] (1'-107') -IGKC*01
                                       (108'-214')]; dímero (223-223'':226-226'':228-228'')-
                                       trisdisulfuro
                                       Heavy chain / Chaîne lourde / Cadena pesada
                                       EIQLQQSGPE LVKPGASVKV SCKASGYSFT                  DYNMYWVKQS       HGKSLEWIGY        50
                                       IDPYNGDTTY NQKFKGKATL TVDKSSSTAF                  IHLNSLTSED       SAVYYCARSP       100
                                       YGHYAMDYWG QGTSVTVSSA KTTPPSVYPL                  APGSAAQTNS       MVTLGCLVKG       150
                                       YFPEPVTVTW NSGSLSSGVH TFPAVLQSDL                  YTLSSSVTVP       SSTWPSETVT       200
                                       CNVAHPASST KVDKKIVPRD CGCKPCICTV                  PEVSSVFIFP       PKPKDVLTIT       250
                                       LTPKVTCVVV DISKDDPEVQ FSWFVDDVEV                  HTAQTQPREE       QFNSTFRSVS       300
                                       ELPIMHQDWL NGKEFKCRVN SAAFPAPIEK                  TISKTKGRPK       APQVYTIPPP       350
                                       KEQMAKDKVS LTCMITDFFP EDITVEWQWN                  GQPAENYKNT       QPIMDTDGSY       400
                                       FVYSKLNVQK SNWEAGNTFT CSVLHEGLHN                  HHTEKSLSHS       PGK              443

                                       Light chain / Chaîne légère / Cadena ligera
                                       DIVMTQSHKL LSTSVGDRVS ITCKASQDVS                  TAVDWYQQKP       GQSPKLLINW 50
                                       ASTRHTGVPD RFTGSGSGTD YTLTISSMQA                  EDLALYYCRQ       HYSTPFTFGS 100
                                       GTKLEIKRAD AAPTVSIFPP SSEQLTSGGA                  SVVCFLNNFY       PKDINVKWKI 150
                                       DGSERQNGVL NSWTDQDSKD STYSMSSTLT                  LTKDEYERHN       SYTCEATHKT 200
                                       STSPIVKSFN RNEC                                                               214

                                       Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro
                                       Intra-H (C23-C104) 22-96          146-201      257-317    363-421
                                                             22''-96'' 146''-201'' 257''-317'' 363''-421''
                                       Intra-L (C23-C104) 23'-88'         134'-194'
                                                              23'''-88''' 134'''-194'''
                                       Inter-H-L (h 5-CL 126)        221-214' 221''-214'''
                                       Inter-H-H (h 7, h 10, h 12) 223-223'' 226-226'' 228-228''

                                       N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación
                                       H CH2 N84.4:
                                       293, 293''


 lokivetmabum #
 lokivetmab                            immunoglobulin G2-kappa, anti-[Canis lupus familiaris IL31
                                       (interleukin 31)], caninized monoclonal antibody;
                                       gamma2 heavy chain (1-452) [caninized VH (Canis lupus
                                       familiaris IGHV-E2RCC8 (85.90%) -(IGHD)-IGHJ) [8.8.11]
                                       (1-118) -Canis lupus familiaris IGHG2*01 (CH1 (119-216),
                                       hinge (217-234), CH2 (235-344), CH3 (345-451), CHS
                                       (452)) (119-452)], (133-217')-disulfide with kappa light
                                       chain (1'-217') [caninized V-KAPPA (Canis lupus familiaris
                                       IGKV-F1PNY2 (56.00%) -IGKJ) [10.3.9] (1'-111') -Canis
                                       lupus familiaris IGKC*01 (112'-217')]; dimer (230-230'':233-
                                       233'')-bisdisulfide




                                                                                                                                 407
Recommended INN: List 74                                       WHO Drug Information, Vol. 29, No. 3, 2015


 lokivetmab                                    immunoglobuline G2-kappa, anti-[Canis lupus familiaris IL31
                                               (interleukine 31)], anticorps monoclonal caninisé;
                                               chaîne lourde gamma2 (1-452) [VH caninisé (Canis lupus
                                               familiaris IGHV-E2RCC8 (85.90%) -(IGHD)-IGHJ) [8.8.11] (1-
                                               118) -Canis lupus familiaris IGHG2*01 (CH1 (119-216),
                                               charnière (217-234), CH2 (235-344), CH3 (345-451), CHS
                                               (452)) (119-452)], (133-217')-disulfure avec la chaîne légère
                                               kappa (1'-217') [V-KAPPA caninisé (Canis lupus familiaris
                                               IGKV-F1PNY2 (56.00%) -IGKJ) [10.3.9] (1'-111') -Canis lupus
                                               familiaris IGKC*01 (112'-217')]; dimère (230-230'':233-233'')-
                                               bisdisulfure
 lokivetmab                                    inmunoglobulina G2-kappa, anti-[Canis lupus familiaris IL31
                                               (interleukina 31)], anticuerpo monoclonal caninizado;
                                               cadena pesada gamma2 (1-452) [VH caninizado (Canis lupus
                                               familiaris IGHV-E2RCC8 (85.90%) -(IGHD)-IGHJ) [8.8.11] (1-
                                               118) -Canis lupus familiaris IGHG2*01 (CH1 (119-216),
                                               bisagra (217-234), CH2 (235-344), CH3 (345-451), CHS (452))
                                               (119-452)], (133-217')-disulfuro con la caden ligera kappa (1'-
                                               217') [V-KAPPA caninizado (Canis lupus familiaris IGKV-
                                               F1PNY2 (56.00%) -IGKJ) [10.3.9] (1'-111') -Canis lupus
                                               familiaris IGKC*01 (112'-217')]; dímero (230-230'':233-233'')-
                                               bisdisulfuro
                                                Heavy chain / Chaîne lourde / Cadena pesada
                                                EVQLVESGGD LVKPGGSLRL SCVASGFTFS                  NYGMSWVRQA       PGKGLQWVAT        50
                                                ISYGGSYTYY PDNIKGRFTI SRDNAKNTLY                  LQMNSLRAED       TAMYYCVRGY       100
                                                GYDTMDYWGQ GTLVTVSSAS TTAPSVFPLA                  PSCGSTSGST       VALACLVSGY       150
                                                FPEPVTVSWN SGSLTSGVHT FPSVLQSSGL                  YSLSSMVTVP       SSRWPSETFT       200
                                                CNVAHPASKT KVDKPVPKRE NGRVPRPPDC                  PKCPAPEMLG       GPSVFIFPPK       250
                                                PKDTLLIART PEVTCVVVDL DPEDPEVQIS                  WFVDGKQMQT       AKTQPREEQF       300
                                                NGTYRVVSVL PIGHQDWLKG KQFTCKVNNK                  ALPSPIERTI       SKARGQAHQP       350
                                                SVYVLPPSRE ELSKNTVSLT CLIKDFFPPD                  IDVEWQSNGQ       QEPESKYRTT       400
                                                PPQLDEDGSY FLYSKLSVDK SRWQRGDTFI                  CAVMHEALHN       HYTQESLSHS       450
                                                PG                                                                                  452

                                                Light chain / Chaîne légère / Cadena ligera
                                                EIVMTQSPAS LSLSQEEKVT ITCKASQSVS                  FAGTGLMHWY       QQKPGQAPKL 50
                                                LIYRASNLEA GVPSRFSGSG SGTDFSFTIS                  SLEPEDVAVY       YCQQSREYPW 100
                                                TFGQGTKLEI KRNDAQPAVY LFQPSPDQLH                  TGSASVVCLL       NSFYPKDINV 150
                                                KWKVDGVIQD TGIQESVTEQ DKDSTYSLSS                  TLTMSSTEYL       SHELYSCEIT 200
                                                HKSLPSTLIK SFQRSEC                                                            217

                                                Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro
                                                Intra-H (C23-C104) 22-96          145-201      265-325    371-431
                                                                      22''-96'' 145''-201'' 265''-325'' 371''-431''
                                                Intra-L (C23-C104) 23'-92'         138'-197'
                                                                       23'''-92''' 138'''-197'''
                                                Inter-H-L (CH1 11-CL 126) 133-217' 133''-217'''
                                                Inter-H-H (h 14, h 17)         230-230'' 233-233''

                                                N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación
                                                H CH2 N84.4:
                                                301, 301''

                                                Other post-translational modifications / Autres modifications post-traductionnelles / Otras
                                                modificaciones post-traduccionales
                                                Lacking H chain C-terminal lysine (CHS K2>del)


 lutetium (177Lu) lilotomabum satetraxetanum #
 lutetium (177Lu) lilotomab satetraxetan    immunoglobulin G1-kappa, anti-[Homo sapiens CD37
                                            (TSPAN26, tetraspanin-26)], Mus musculus monoclonal
                                            antibody, lutetium (Lu 177) radiolabelled satetraxetan (DOTA
                                            derivative) conjugate;
                                            gamma1 heavy chain (1-443) [Mus musculus VH
                                            (IGHV1S135*01 (96.90%) -(IGHD)-IGHJ4*01) [8.8.12]
                                            (1-119) -IGHG1*01 (CH1 E84>Q (177), P95>T (193), R96>W
                                            (194) (120-216), hinge (217-229), CH2 (230-336), CH3
                                            N84.2>D (395), N84.4>D (397) (337-441), CHS (442-443))
                                            (120-443)], (221-214')-disulfide with kappa light chain (1'-214')
                                            [Mus musculus V-KAPPA (IGKV6-25*01 (93.70%) -IGKJ4*01)
                                            [6.3.9] (1'-107') -IGKC*01 (108'-214')]; dimer (223-223'':226-
                                            226'':228-228'')-trisdisulfide, an average of 1 to 2 amino groups
                                            (N6 of lysines) are substituted:
                                            N-[rac-(4-{[(2R)-1,4,7,10-tetrakis(carboxymethyl)-1,4,7,10-
                                            tetraazacyclododecan-2-yl]methyl}phenyl)carbamothioyl]
                                            (177Lu)lutetium(3+) chelate




408
WHO Drug Information, Vol. 29, No. 3, 2015                                                            Recommended INN: List 74


 lutécium (177Lu) lilotomab satétraxétan   immunoglobuline G1-kappa, anti-[Homo sapiens CD37
                                           (TSPAN26, tétraspanine-26)], Mus musculus anticorps
                                           monoclonal; conjugué au satétraxétan (dérivé DOTA)
                                           radiomarqué au lutétium (Lu 177);
                                           chaîne lourde gamma1 (1-443) [Mus musculus VH
                                           (IGHV1S135*01 (96.90%) -(IGHD)-IGHJ4*01) [8.8.12]
                                           (1-119) -IGHG1*01 (CH1 E84>Q (177), P95>T (193), R96>W
                                           (194) (120-216), charnière (217-229), CH2 (230-336), CH3
                                           N84.2>D (395), N84.4>D (397) (337-441), CHS (442-443))
                                           (120-443)], (221-214')-disulfure avec la chaîne légère kappa
                                           (1'-214') [Mus musculus V-KAPPA (IGKV6-25*01 (93.70%) -
                                           IGKJ4*01) [6.3.9] (1'-107') -IGKC*01 (108'-214')]; dimère (223-
                                           223'':226-226'':228-228'')-trisdisulfure, une moyenne de 1 à 2
                                           groupes amino (N6 de lysines) sont substitués:
                                           N-[rac-(4-{[(2R)-1,4,7,10-tétrakis(carboxyméthyl)-1,4,7,10-
                                           tétraazacyclododécan-2-yl]méthyl}phényl)carbamothioyl]
                                           chélate de (177Lu)lutétium(3+)

 lutecio (177Lu) lilotomab satetraxetán    inmunoglobulina G1-kappa, anti-[CD37 de Homo sapiens
                                           (TSPAN26, tetraspanina-26)], anticuerpo monoclonal de Mus
                                           musculus, conjugada al satetraxetán (derivado DOTA)
                                           radiomarcado con lutecio (Lu 177);
                                           cadena pesada gamma1 (1-443) [VH de Mus musculus
                                           (IGHV1S135*01 (96.90%) -(IGHD)-IGHJ4*01) [8.8.12]
                                           (1-119) -IGHG1*01 (CH1 E84>Q (177), P95>T (193), R96>W
                                           (194) (120-216), bisagra (217-229), CH2 (230-336), CH3
                                           N84.2>D (395), N84.4>D (397) (337-441), CHS (442-443))
                                           (120-443)], (221-214')-disulfuro con la cadena ligera kappa (1'-
                                           214') [Mus musculus V-KAPPA (IGKV6-25*01 (93.70%) -
                                           IGKJ4*01) [6.3.9] (1'-107') -IGKC*01 (108'-214')]; dímero (223-
                                           223'':226-226'':228-228'')-trisdisulfuro; pro termino medio, 1 a 2
                                           groupos amino
                                           (N6 de lisinas) están sustituidos:
                                           N-[rac-(4-{[(2R)-1,4,7,10-tetrakis(carboximetil)-1,4,7,10-
                                           tetraazaciclododecan-2-il]metil}fenil)carbamotioil] quelato de
                                           (177Lu)lutecio(3+)
                                           Heavy chain / Chaîne lourde / Cadena pesada
                                           EIQLQQSGPE LVKPGASVKV SCKASGYSFT                            DYNMYWVKQS        HGKSLEWIGY    50
                                           IDPYNGDTTY NQKFKGKATL TVDKSSSTAF                            IHLNSLTSED        SAVYYCARSP   100
                                           YGHYAMDYWG QGTSVTVSSA KTTPPSVYPL                            APGSAAQTNS        MVTLGCLVKG   150
                                           YFPEPVTVTW NSGSLSSGVH TFPAVLQSDL                            YTLSSSVTVP        SSTWPSETVT   200
                                           CNVAHPASST KVDKKIVPRD CGCKPCICTV                            PEVSSVFIFP        PKPKDVLTIT   250
                                           LTPKVTCVVV DISKDDPEVQ FSWFVDDVEV                            HTAQTQPREE        QFNSTFRSVS   300
                                           ELPIMHQDWL NGKEFKCRVN SAAFPAPIEK                            TISKTKGRPK        APQVYTIPPP   350
                                           KEQMAKDKVS LTCMITDFFP EDITVEWQWN                            GQPAENYKNT        QPIMDTDGSY   400
                                           FVYSKLNVQK SNWEAGNTFT CSVLHEGLHN                            HHTEKSLSHS        PGK          443

                                           Light chain / Chaîne légère / Cadena ligera
                                           DIVMTQSHKL LSTSVGDRVS ITCKASQDVS                            TAVDWYQQKP        GQSPKLLINW 50
                                           ASTRHTGVPD RFTGSGSGTD YTLTISSMQA                            EDLALYYCRQ        HYSTPFTFGS 100
                                           GTKLEIKRAD AAPTVSIFPP SSEQLTSGGA                            SVVCFLNNFY        PKDINVKWKI 150
                                           DGSERQNGVL NSWTDQDSKD STYSMSSTLT                            LTKDEYERHN        SYTCEATHKT 200
                                           STSPIVKSFN RNEC                                                                          214

                                           Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro
                                           Intra-H (C23-C104) 22-96          146-201      257-317 363-421
                                                                 22''-96'' 146''-201'' 257''-317'' 363''-421''
                                           Intra-L (C23-C104) 23'-88'         134'-194'
                                                                  23'''-88''' 134'''-194'''
                                           Inter-H-L (h 5-CL 126)        221-214' 221''-214'''
                                           Inter-H-H (h 7, h 10, h 12) 223-223'' 226-226'' 228-228''

                                           N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación
                                           H CH2 N84.4:
                                           293, 293''

                                           Modified residues / Résidus modifiés / Restos modificados
                                                                                 rac               O2C
                                                                                                                                R         =
                                                                 K
                                            An average of 1 to 2 are N-substituted by R        O2C
                                               Environ 1 à 2 sont N-substitués par R                    N            N
                                           Una medida de 1 a 2 están N-sustituidos por R   H                                          S
                                                                                                            177
                                                                                                              Lu3+       H
                                                                                                                                      C
                                                                                                                                 N
                                                                                                        N            N           H
                                                                                               O 2C                      CO2




                                                                                                                                              409
Recommended INN: List 74             WHO Drug Information, Vol. 29, No. 3, 2015




 motolimodum
 motolimod                 2-amino-N,N-dipropyl-8-[4-(pyrrolidine-1-carbonyl)phenyl]-
                           3H-1-benzazepine-4-carboxamide

 motolimod                 2-amino-N,N-dipropyl-8-[4-(pyrrolidine-1-carbonyl)phényl]-
                           3H-1-benzazépine-4-carboxamide

 motolimod                 2-amino-N,N-dipropil-8-[4-(pirrolidina-1-carbonil)fenil]-
                           3H-1-benzazepina-4-carboxamida

                           C28H34N4O2

                                     O

                                 N
                                                               NH2
                                                         N
                                                                         CH3


                                                                   N
                                                              O
                                                                           CH3




 necuparanibum
 necuparanib               low molecular mass heparan sulfate mimetic compound
                           that is obtained by nitrous sodium depolymerization of
                           heparin from porcine intestinal mucosa, sodium periodate
                           glycol split oxidation of uronic acids elements and sodium
                           borohydride reduction of aldehydes produced during
                           oxidation; the majority of the components have a splited
                           uronic acid structure at the non-reducing end and a
                           2,5-anhydromannitol structure at the reducing end of their
                           chain; the average molecular weight range is 5000 to 8000
                           Da; the degree of sulfatation is about 2 per disaccharidic
                           unit

 nécuparanib               dérivé de basse masse moléculaire à action mimétique du
                           sulfate d’héparane, obtenu par dépolymérisation
                           d’héparine de muqueuse intestinale de porc, catalysée par
                           du nitrite de sodium, puis dégradation oxydative des
                           glycols des unités uroniques par le périodate de sodium et
                           réduction, par le borohydrure de sodium, des aldéhydes
                           produits ; la majorité des composants ont, une structure
                           éclatée d’acide uronique à leur extrémité non-réductrice et
                           une structure 2,5-anhydromannitol à leur extrémité
                           réductrice, une masse molaire comprise entre 4500 et
                           7200 daltons et un degré de sulfatation d’environ de 2 par
                           unité disaccharide




410
WHO Drug Information, Vol. 29, No. 3, 2015                                                  Recommended INN: List 74


 necuparanib                           derivado de baja masa molecular de acción mimética de la
                                       del sulfato de heparán, obtenido por despolimerización de
                                       heparina de mucosa intestinal de cerdo, catalizada por
                                       nitrito de sodio, seguida de degradación oxidativa, con
                                       peryodato de sodio, de los glicoles de las unidades
                                       urónicas y reducción, con borohidruro de sodio, de los
                                       aldehídos producidos; la mayoría de los componentes
                                       tienen , una estructura abierta de ácido urónico en su
                                       extremo no-reductor y una estructura 2,5-anhidromanitol
                                       en el reductor, el peso molecular medio está comprendido
                                       entre 4500 y 7200 daltons et el grado de sulfatación es
                                       aproximadamente de 2 por unidad de disacárido

                                                     OR1                                         OR1                                   OR1
                                                               HO2C                                       HO2C
                                                       O                  O                        O                O
                                                                                                                                           O
                                        R    O                 O                       O                  O                  O

                                             R1O     NH            HO         O         R1O          NH       HO        OH        HO
                                                                                                                                            HO
                                                HO3S                    HO3S                       R2
                                                                                   n                                         n'

                                        n = 6 - 12                                     HO2C                              HO2C
                                                                                                   O               or                  O
                                        n' = 1 - 2
                                                                    R          =       HO                          ou   HO
                                        R1 = H, SO3H                                                                ó

                                        R2 = COCH3, SO3H                                    HO         O SO3H                              OH



 neloniclinum
 nelonicline                           (3R,4s,5S)-4-[(5-phenyl-1,3,4-thiadiazol-2-yl)oxy]-
                                       1-azaadamantane

 nélonicline                           (3R,4s,5S)-4-[(5-phényl-1,3,4-thiadiazol-2-yl)oxy]-
                                       1-azaadamantane

 neloniclina                           (3R,4s,5S)-4-[(5-fenil-1,3,4-tiadiazol-2-il)oxi]-
                                       1-azaadamantano

                                       C17H19N3OS


                                                               N N
                                             N
                                                           O        S


 nemolizumabum #
 nemolizumab                           immunoglobulin G2-kappa, anti-[Homo sapiens IL31RA
                                       (interleukin 31 receptor subunit alpha)], humanized
                                       monoclonal antibody;
                                       gamma2 heavy chain (1-445) [humanized VH (Homo
                                       sapiens IGHV1-2*02 (83.70%) -(IGHD)-IGHJ5*01) [8.8.14]
                                       (1-121) -Homo sapiens IGHG2*01 (CH1 C10>S (135),
                                       R12>K (137), E16>G (141), S17>G (142) (122-219), hinge
                                       C4>S (223) (220-231), CH2 H30>Q (268) (232-340), CH3
                                       R11>Q (355), Q98>E (419) (341-445)) (122-445)], (224-
                                       214')-disulfide with kappa light chain (1’-214’) [humanized
                                       V-KAPPA (Homo sapiens IGKV1-39*01 (82.10%) -
                                       IGKJ4*01) [6.3.9] (1'-107') -Homo sapiens IGKC*01 (108'-
                                       214')]; dimer (227-227":230-230")-bisdisulfide




                                                                                                                                               411
Recommended INN: List 74                WHO Drug Information, Vol. 29, No. 3, 2015




 némolizumab               immunoglobuline G2-kappa, anti-[Homo sapiens IL31RA
                           (sous-unité alpha du récepteur de l’interleukine 31)],
                           anticorps monoclonal humanisé;
                           chaîne lourde gamma2 (1-445) [VH humanisé (Homo
                           sapiens IGHV1-2*02 (83.70%) -(IGHD)-IGHJ5*01) [8.8.14]
                           (1-121) -Homo sapiens IGHG2*01 (CH1 C10>S (135),
                           R12>K (137), E16>G (141), S17>G (142) (122-219),
                           charnière C4>S (223) (220-231), CH2 H30>Q (268) (232-
                           340), CH3 R11>Q (355), Q98>E (419) (341-445)) (122-
                           445)], (224-214')-disulfure avec la chaîne légère kappa
                           (1’-214’) [V-KAPPA humanisé (Homo sapiens IGKV1-
                           39*01 (82.10%) -IGKJ4*01) [6.3.9] (1'-107') -Homo sapiens
                           IGKC*01 (108'-214')]; dimère (227-227":230-230")-
                           bisdisulfure

 nemolizumab               inmunoglobulina G2-kappa, anti-[IL31RA de Homo sapiens
                           (subunidad alfa del receptor de la interleukina 31)],
                           anticuerpo monoclonal humanizado;
                           cadena pesada gamma2 (1-445) [VH humanizado (Homo
                           sapiens IGHV1-2*02 (83.70%) -(IGHD)-IGHJ5*01) [8.8.14]
                           (1-121) -Homo sapiens IGHG2*01 (CH1 C10>S (135),
                           R12>K (137), E16>G (141), S17>G (142) (122-219),
                           bisagra C4>S (223) (220-231), CH2 H30>Q (268) (232-
                           340), CH3 R11>Q (355), Q98>E (419) (341-445)) (122-
                           445)], (224-214')-disulfuro con la cadena ligera kappa
                           (1’-214’) [V-KAPPA humanizado (Homo sapiens IGKV1-
                           39*01 (82.10%) -IGKJ4*01) [6.3.9] (1'-107') -Homo sapiens
                           IGKC*01 (108'-214')]; dímero (227-227":230-230")-
                           bisdisulfuro
                           Heavy chain / Chaîne lourde / Cadena pesada
                           QVQLVQSGAE VKKPGASVKV SCKASGYTFT                  GYIMNWVRQA       PGQGLEWMGL        50
                           INPYNGGTDY NPQFQDRVTI TADKSTSTAY                  MELSSLRSED       TAVYYCARDG       100
                           YDDGPYTLET WGQGTLVTVS SASTKGPSVF                  PLAPSSKSTS       GGTAALGCLV       150
                           KDYFPEPVTV SWNSGALTSG VHTFPAVLQS                  SGLYSLSSVV       TVPSSNFGTQ       200
                           TYTCNVDHKP SNTKVDKTVE RKSCVECPPC                  PAPPVAGPSV       FLFPPKPKDT       250
                           LMISRTPEVT CVVVDVSQED PEVQFNWYVD                  GVEVHNAKTK       PREEQFNSTF       300
                           RVVSVLTVVH QDWLNGKEYK CKVSNKGLPA                  PIEKTISKTK       GQPREPQVYT       350
                           LPPSQEEMTK NQVSLTCLVK GFYPSDIAVE                  WESNGQPENN       YKTTPPMLDS       400
                           DGSFFLYSKL TVDKSRWQEG NVFSCSVMHE                  ALHNHYTQKS       LSLSP            445

                           Light chain / Chaîne légère / Cadena ligera
                           DIQMTQSPSS LSASVGDRVT ITCQASEDIY                  SFVAWYQQKP       GKAPKLLIYN 50
                           AQTEAQGVPS RFSGSGSGTD FTLTISSLQP                  EDFATYYCQH       HYDSPLTFGG 100
                           GTKVEIKRTV AAPSVFIFPP SDEQLKSGTA                  SVVCLLNNFY       PREAKVQWKV 150
                           DNALQSGNSQ ESVTEQDSKD STYSLSSTLT                  LSKADYEKHK       VYACEVTHQG 200
                           LSSPVTKSFN RGEC                                                               214

                           Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro
                           Intra-H (C23-C104) 22-96          148-204       261-321   367-425
                                                  22''-96'' 148''-204'' 261''-321'' 367''-425''
                           Intra-L (C23-C104) 23'-88' 134'-194'
                                                 23'''-88''' 134'''-194'''
                           Inter-H-L (h 5-CL 126) 224-214' 224''-214'''
                           Inter-H-H (h 8, h 11)      227-227'' 230-230''

                           N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación
                           H CH2 N84.4:
                           297, 297''

                           Other post-translational modifications / Autres modifications post-traductionnelles / Otras
                           modificaciones post-traduccionales
                           Lacking H chain C-terminal glycine and lysine (CHS G1>del, K2>del)




412
WHO Drug Information, Vol. 29, No. 3, 2015                           Recommended INN: List 74




 nusinersenum
 nusinersen                            all-P-ambo-2'-O-(2-methoxyethyl)-5-methyl-P-thiouridylyl-
                                       (3'→5')-2'-O-(2-methoxyethyl)-5-methyl-P-thiocytidylyl-
                                       (3'→5')-2'-O-(2-methoxyethyl)-P-thioadenylyl-(3'→5')-2'-O-
                                       (2-methoxyethyl)-5-methyl-P-thiocytidylyl-(3'→5')-2'-O-(2-
                                       methoxyethyl)-5-methyl-P-thiouridylyl-(3'→5')-2'-O-(2-
                                       methoxyethyl)-5-methyl-P-thiouridylyl-(3'→5')-2'-O-(2-
                                       methoxyethyl)-5-methyl-P-thiouridylyl-(3'→5')-2'-O-(2-
                                       methoxyethyl)-5-methyl-P-thiocytidylyl-(3'→5')-2'-O-(2-
                                       methoxyethyl)-P-thioadenylyl-(3'→5')-2'-O-(2-
                                       methoxyethyl)-5-methyl-P-thiouridylyl-(3'→5')-2'-O-(2-
                                       methoxyethyl)-P-thioadenylyl-(3'→5')-2'-O-(2-
                                       methoxyethyl)-P-thioadenylyl-(3'→5')-2'-O-(2-
                                       methoxyethyl)-5-methyl-P-thiouridylyl-(3'→5')-2'-O-(2-
                                       methoxyethyl)-P-thioguanylyl-(3'→5')-2'-O-(2-
                                       methoxyethyl)-5-methyl-P-thiocytidylyl-(3'→5')-2'-O-(2-
                                       methoxyethyl)-5-methyl-P-thiouridylyl-(3'→5')-2'-O-(2-
                                       methoxyethyl)-P-thioguanylyl-(3'→5')-2'-O-(2-
                                       methoxyethyl)guanosine

 nusinersen                            tout-P-ambo-2'-O-(2-méthoxyéthyl)-5-méthyl-P-thiouridylyl-
                                       (3'→5')-2'-O-(2-méthoxyéthyl)-5-méthyl-P-thiocytidylyl-
                                       (3'→5')-2'-O-(2-méthoxyéthyl)-P-thioadénylyl-(3'→5')-2'-O-
                                       (2-méthoxyéthyl)-5-méthyl-P-thiocytidylyl-(3'→5')-2'-O-(2-
                                       méthoxyéthyl)-5-méthyl-P-thiouridylyl-(3'→5')-2'-O-(2-
                                       méthoxyéthyl)-5-méthyl-P-thiouridylyl-(3'→5')-2'-O-(2-
                                       méthoxyéthyl)-5-méthyl-P-thiouridylyl-(3'→5')-2'-O-(2-
                                       méthoxyéthyl)-5-méthyl-P-thiocytidylyl-(3'→5')-2'-O-(2-
                                       méthoxyéthyl)-P-thioadénylyl-(3'→5')-2'-O-(2-
                                       méthoxyéthyl)-5-méthyl-P-thiouridylyl-(3'→5')-2'-O-(2-
                                       méthoxyéthyl)-P-thioadénylyl-(3'→5')-2'-O-(2-
                                       méthoxyéthyl)-P-thioadénylyl-(3'→5')-2'-O-(2-
                                       méthoxyéthyl)-5-méthyl-P-thiouridylyl-(3'→5')-2'-O-(2-
                                       méthoxyéthyl)-P-thioguanylyl-(3'→5')-2'-O-(2-
                                       méthoxyéthyl)-5-méthyl-P-thiocytidylyl-(3'→5')-2'-O-(2-
                                       méthoxyéthyl)-5-méthyl-P-thiouridylyl-(3'→5')-2'-O-(2-
                                       méthoxyéthyl)-P-thioguanylyl-(3'→5')-2'-O-(2-
                                       méthoxyéthyl)guanosine

 nusinersén                            todo-P-ambo-2'-O-(2-metoxietil)-5-metil-P-tiouridilil-(3'→5')-
                                       2'-O-(2-metoxietil)-5-metil-P-tiocitidilil-(3'→5')-2'-O-(2-
                                       metoxietil)-P-tioadenilil-(3'→5')-2'-O-(2-metoxietil)-5-metil-
                                       P-tiocitidilil-(3'→5')-2'-O-(2-metoxietil)-5-metil-P-tiouridilil-
                                       (3'→5')-2'-O-(2-metoxietil)-5-metil-P-tiouridilil-(3'→5')-2'-O-
                                       (2-metoxietil)-5-metil-P-tiouridilil-(3'→5')-2'-O-(2-metoxietil)-
                                       5-metil-P-tiocitidilil-(3'→5')-2'-O-(2-metoxietil)-P-tioadenilil-
                                       (3'→5')-2'-O-(2-metoxietil)-5-metil-P-tiouridilil-(3'→5')-2'-O-
                                       (2-metoxietil)-P-tioadenilil-(3'→5')-2'-O-(2-metoxietil)-P-
                                       tioadenilil-(3'→5')-2'-O-(2-metoxietil)-5-metil-P-tiouridilil-
                                       (3'→5')-2'-O-(2-metoxietil)-P-tioguanilil-(3'→5')-2'-O-(2-
                                       metoxietil)-5-metil-P-tiocitidilil-(3'→5')-2'-O-(2-metoxietil)-5-
                                       metil-P-tiouridilil-(3'→5')-2'-O-(2-metoxietil)-P-tioguanilil-
                                       (3'→5')-2'-O-(2-metoxietil)guanosina




                                                                                                   413
Recommended INN: List 74                     WHO Drug Information, Vol. 29, No. 3, 2015




                           C234H340N61O128P17S17
                           [2'-O-(2-methoxyethyl)](3'-5')(P-thio)(mU-mC-A-mC-mU-mU-mU-mC-A-mU-A-
                                                                   A-mU-G-mC-mU-G-G)
                                                         H2N
                            A                   G                    mC              mU
                                             N                             NH
                                     N             NH2             N               O                                                    H
                                                                                                O       N       NH2            O        N    O
                            OH                           OH                            OH                             OH
                                 O       N    N                O       N       N            O       N                      O        N
                                                                                                                CH3                          CH3
                                                 OCH3                          OCH3                         OCH3                            OCH3
                            HO       O                    HO       O                   HO       O                     HO        O




 onalespibum
 onalespib                 [2,4-dihydroxy-5-(propan-2-yl)phenyl]{5-[(4-
                           methylpiperazin-1-yl)methyl]-1,3-dihydro-2H-isoindol-
                           2-yl}methanone

 onalespib                 [2,4-dihydroxy-5-(propan-2-yl)phényl]{5-[(4-
                           méthylpipérazin-1-yl)méthyl]-1,3-dihydro-2H-isoindol-
                           2-yl}méthanone

 onalespib                 [2,4-dihidroxi-5-(propan-2-il)fenil]{5-[(4-metilpiperazin-
                           1-il)metil]-1,3-dihidro-2H-isoindol-2-il}metanona

                           C24H31N3O3

                                                                                                                CH3
                                     CH3                      O                                             N

                            H3 C                                   N
                                                                                                    N
                                   HO                         OH



 ozanimodum
 ozanimod                  5-(3-{(1S)-1-[(2-hydroxyethyl)amino]-2,3-dihydro-1H-inden-
                           4-yl}-1,2,4-oxadiazol-5-yl)-2-[(propan-2-yl)oxy]benzonitrile

 ozanimod                  5-(3-{(1S)-1-[(2-hydroxyéthyl)amino]-2,3-dihydro-1H-indén-
                           4-yl}-1,2,4-oxadiazol-5-yl)-2-[(propan-2-yl)oxy]benzonitrile

 ozanimod                  5-(3-{(1S)-1-[(2-hidroxietil)amino]-2,3-dihidro-1H-inden-
                           4-il}-1,2,4-oxadiazol-5-il)-2-[(propan-2-il)oxi]benzonitrilo

                           C23H24N4O3

                                                                           N
                                                                   O

                                     CH3                                   N
                                                                                                        H
                                                                                                                           OH
                            H3 C             O                                                          N
                                                                                                        H
                                                         CN




414
WHO Drug Information, Vol. 29, No. 3, 2015                            Recommended INN: List 74




 pegpleranibum
 pegpleranib                           5’-O-{[(6-{N2,N6-bis[α-carbonyl-ω-methoxypoly(oxyethane-1,2-
                                       diyl)]-DL-lysylamido}hexyl)oxy]hydroxyphosphoryl}-2’-
                                       deoxycytidylyl-(3’→5’)-2’-deoxyadenylyl-(3’→5’)-2’-
                                       deoxyguanylyl-(3’→5’)-2’-deoxyguanylyl-(3’→5’)-2’-
                                       deoxycytidylyl-(3’→5’)-2’-deoxy-2’-fluorouridylyl-(3’→5’)-2’-
                                       deoxyadenylyl-(3’→5’)-2’-deoxy-2’-fluorocytidylyl-(3’→5’)-2’-O-
                                       methylguanylyl-(3’→17)-hydroxy[(17-hydroxy-3,6,9,12,15-
                                       pentaoxaheptadecyl)oxy]phosphoryl-(1→5’)-2’-deoxycytidylyl-
                                       (3’→5’)-2’-deoxyguanylyl-(3’→5’)-thymidylyl-(3’→5’)-2’-
                                       deoxyadenylyl-(3’→5’)-2’-O-methylguanylyl-(3’→5’)-2’-
                                       deoxyadenylyl-(3’→5’)-2’-O-methylguanylyl-(3’→5’)-2’-
                                       deoxycytidylyl-(3’→5’)-2’-deoxyadenylyl-(3’→5’)-2’-deoxy-2’-
                                       fluorouridylyl-(3’→5’)-2’-deoxy-2’-fluorocytidylyl-(3’→5’)-2’-O-
                                       methyladenylyl-(3’→17)-hydroxy[(17-hydroxy-3,6,9,12,15-
                                       pentaoxaheptadecyl) oxy]phosphoryl-(1→5’)-thymidylyl-
                                       (3’→5’)-2’-deoxyguanylyl-(3’→5’)-2’-deoxyadenylyl-(3’→5’)-
                                       thymidylyl-(3’→5’)-2’-deoxy-2’-fluorocytidylyl-(3’→5’)-2’-deoxy-
                                       2’-fluorocytidylyl-(3’→5’)-2’-deoxy-2’-fluorouridylyl-(3’→5’)-2’-O-
                                       methylguanylyl-(3’→3’)-thymidine

 pegpléranib                           5’-O-{[(6-{N2,N6-bis[α-carbonyl-ω-méthoxypoly(oxyéthane-1,2-
                                       diyl)]-DL-lysylamido}hexyl)oxy]hydroxyphosphoryl}-2’-
                                       déoxycytidylyl-(3’→5’)-2’-déoxyadénylyl-(3’→5’)-2’-
                                       déoxyguanylyl-(3’→5’)-2’-déoxyguanylyl-(3’→5’)-2’-
                                       déoxycytidylyl-(3’→5’)-2’-déoxy-2’-fluorouridylyl-(3’→5’)-2’-
                                       déoxyadénylyl-(3’→5’)-2’-déoxy-2’-fluorocytidylyl-(3’→5’)-2’-O-
                                       méthylguanylyl-(3’→17)-hydroxy[(17-hydroxy-3,6,9,12,15-
                                       pentaoxaheptadécyl)oxy]phosphoryl-(1→5’)-2’-déoxycytidylyl-
                                       (3’→5’)-2’-déoxyguanylyl-(3’→5’)-thymidylyl-(3’→5’)-2’-
                                       déoxyadénylyl-(3’→5’)-2’-O-méthylguanylyl-(3’→5’)-2’-
                                       déoxyadénylyl-(3’→5’)-2’-O-méthylguanylyl-(3’→5’)-2’-
                                       déoxycytidylyl-(3’→5’)-2’-déoxyadénylyl-(3’→5’)-2’-déoxy-2’-
                                       fluorouridylyl-(3’→5’)-2’-déoxy-2’-fluorocytidylyl-(3’→5’)-2’-O-
                                       méthyladénylyl-(3’→17)-hydroxy[(17-hydroxy-3,6,9,12,15-
                                       pentaoxaheptadécyl) oxy]phosphoryl-(1→5’)-thymidylyl-
                                       (3’→5’)-2’-déoxyguanylyl-(3’→5’)-2’-déoxyadénylyl-(3’→5’)-
                                       thymidylyl-(3’→5’)-2’-déoxy-2’-fluorocytidylyl-(3’→5’)-2’-déoxy-
                                       2’-fluorocytidylyl-(3’→5’)-2’-déoxy-2’-fluorouridylyl-(3’→5’)-2’-O-
                                       méthylguanylyl-(3’→3’)-thymidine

 pegpleranib                           5’-O-{[(6-{N2,N6-bis[α-carbonil-ω-metoxipoli(oxietano-1,2-diil)]-
                                       DL-lisilamido}hexil)oxi]hidroxifosforil}-2’-desoxicitidilil-(3’→5’)-
                                       2’-desoxiadenilil-(3’→5’)-2’-desoxiguanilil-(3’→5’)-2’-
                                       desoxiguanilil-(3’→5’)-2’-desoxicitidilil-(3’→5’)-2’-desoxi-2’-
                                       fluorouridilil-(3’→5’)-2’-desoxiadenilil-(3’→5’)-2’-desoxi-2’-
                                       fluorocitidilil-(3’→5’)-2’-O-metilguanilil-(3’→17)-hidroxi[(17-
                                       hidroxi-3,6,9,12,15-pentaoxaheptadecil) oxi]fosforil-(1→5’)-2’-
                                       desoxicitidilil-(3’→5’)-2’-desoxiguanilil-(3’→5’)-timidilil-(3’→5’)-
                                       2’-desoxiadenilil-(3’→5’)-2’-O-metilguanilil-(3’→5’)-2’-
                                       desoxiadenilil-(3’→5’)-2’-O-metilguanilil-(3’→5’)-2’-
                                       desoxicitidilil-(3’→5’)-2’-desoxiadenilil-(3’→5’)-2’-desoxi-2’-
                                       fluorouridilil-(3’→5’)-2’-desoxi-2’-fluorocitidilil-(3’→5’)-2’-O-
                                       metiladenilil-(3’→17)-hidroxi[(17-hidroxi-3,6,9,12,15-
                                       pentaoxaheptadecil)oxi]fosforil-(1→5’)-timidilil-(3’→5’)-2’-
                                       desoxiguanilil-(3’→5’)-2’-desoxiadenilil-(3’→5’)-timidilil-(3’→5’)-
                                       2’-desoxi-2’-fluorocitidilil-(3’→5’)-2’-desoxi-2’-fluorocitidilil-
                                       (3’→5’)-2’-desoxi-2’-fluorouridilil-(3’→5’)-2’-O-metilguanilil-
                                       (3’→3’)-timidina




                                                                                                      415
Recommended INN: List 74                WHO Drug Information, Vol. 29, No. 3, 2015



                           (3'-5')-R-dC-dA-dG-dG-dC-dUfl-dA-dCfl-Gm3'-17Xp1-
                                      5'dC-dG-dT-dA-Gm-dA-Gm-dC-dA-dUfl-dCfl-Am3'-
                                      17Xp1-5'dT-dG-dA-dT-dCfl-dCfl-dUfl-Gm3'-3'dT
                                                                                        Xp
                             d (as prefix) = 2'-deoxy
                                                                                                        OH
                             fl (as suffix) = 2'-fluoro                                         O
                             m (as suffix) = 2'-O-methyl                        O            6      P
                                                                                                    O
                             x+y=n          R       =               O
                                                                                    O
                                                                N       O               CH3
                                                                H                   y
                             rac
                                                O                                           O
                                                    H       H
                                   O                        N                               P
                             H3C            O     N                                     O
                                                x H                                              OH
                                                        O


 pexidartinibum
 pexidartinib              5-[(5-chloro-1H-pyrrolo[2,3-b]pyridin-3-yl)methyl]-
                           N-{[6-(trifluoromethyl)pyridin-3-yl]methyl}pyridin-2-amine

 pexidartinib              5-[(5-chloro-1H-pyrrolo[2,3-b]pyridin-3-yl)méthyl]-
                           N-{[6-(trifluorométhyl)pyridin-3-yl]méthyl}pyridin-2-amine

 pexidartinib              5-[(5-cloro-1H-pirrolo[2,3-b]piridin-3-il) metil]-
                           N-{[6-(trifluorometil)piridin-3-il]metil}piridin-2-amina

                           C20H15ClF3N5

                                                                                CF3
                                                            H
                                                    N       N               N
                                   HN
                             N



                            Cl

 pinometostatum
 pinometostat              9-{5-deoxy-5-[{cis-3-[2-(5-tert-butyl-1H-benzimidazol-
                           2-yl)ethyl]cyclobutyl}(propan-2-yl)amino]-
                           β-D-ribofuranosyl}-9H-purin-6-amine

 pinométostat              9-{5-déoxy-5-[{cis-3-[2-(5-tert-butyl-1H-benzimidazol-
                           2-yl)éthyl]cyclobutyl}(propan-2-yl)amino]-
                           β-D-ribofuranosyl}-9H-purin-6-amine

 pinometostat              9-{5-desoxi-5-[{cis-3-[2-(5-terc-butil-1H-benzoimidazol-
                           2-il)etil]ciclobutil}(propan-2-il)amino]-β-D-ribofuranosil}-
                           9H-purin-6-amina

                           C30H42N8O3
                                                                            CH3                       N
                                            H           H               H
                                            N                                               N                NH2
                                                                        N       CH3
                                                N                               O           N           N


                            H3C
                                     CH3                                HO              OH
                                   CH3




416
WHO Drug Information, Vol. 29, No. 3, 2015                              Recommended INN: List 74




 radalbuvirum
 radalbuvir                            5-(3,3-dimethylbut-1-yn-1-yl)-3-{(1R)-N-[(1s,4s)-4-hydroxy-
                                       4-({[(3S)-oxolan-3-yl]oxy}methyl)cyclohexyl]-
                                       4-methylcyclohex-3-ene-1-carboxamido}thiophene-
                                       2-carboxylic acid

 radalbuvir                            acide 5-(3,3-diméthylbut-1-yn-1-yl)-3-{(1R)-N-[(1s,4s)-4-
                                       hydroxy-4-({[(3S)-oxolan-3-yl]oxy}méthyl)cyclohexyl]-
                                       4-méthylcyclohex-3-ène-1-carboxamido}thiophène-
                                       2-carboxylique

 radalbuvir                            ácido 5-(3,3-dimetilbut-1-in-1-il)-3-{(1R)-N-[(1s,4s)-4-
                                       hidroxi-4-({[(3S)-oxolan-3-il]oxi}metil)ciclohexil]-
                                       4-metilciclohex-3-eno-1-carboxamido}tiofeno-2-carboxílico

                                       C30H41NO6S

                                                                    CO2H                      O
                                         H3C               S
                                                                    H
                                        H 3C                                            O
                                               CH3                  N                 OH  H
                                                                        H
                                                               O



                                                                                CH3

 ralinepagum
 ralinepag                             {[trans-4-({[(4-chlorophenyl)(phenyl)carbamoyl]
                                       oxy}methyl)cyclohexyl]methoxy}acetic acid

 ralinépag                             acide {[trans-4-({[(4-chlorophényl)(phényl)carbamoyl]
                                       oxy}méthyl)cyclohex-yl]methoxy}acétique

 ralinepag                             ácido {[trans-4-({[(4-clorofenil)(fenil)carbamoil]
                                       oxi}metil)ciclohexil]metoxi}acético

                                       C23H26ClNO5

                                                                            O     CO2H
                                               O       O

                                                   N


                                                               Cl

 relebactamum
 relebactam                            (1R,2S,5R)-7-oxo-2-[(piperidin-4-yl)carbamoyl]-
                                       1,6-diazabicyclo[3.2.1]octan-6-yl hydrogen sulfate

 rélébactam                            hydrogénosulfate de (1R,2S,5R)-7-oxo-2-[(pipéridin-
                                       4-yl)carbamoyl]-1,6-diazabicyclo[3.2.1]octan-6-yle

 relebactam                            hidrógenosulfato de (1R,2S,5R)-7-oxo-2-[(piperidin-
                                       4-il)carbamoil]-7-oxo-1,6-diazabiciclo[3.2.1]octan-6-ilo




                                                                                                  417
Recommended INN: List 74            WHO Drug Information, Vol. 29, No. 3, 2015


                           C12H20N4O6S

                                                     O        NH
                                                 H
                                   O
                                             N           N
                                                         H
                             O O   N
                               S O
                            HO               H



 ridinilazolum
 ridinilazole              2,2'-di(pyridin-4-yl)-1H,1'H-5,5'-bi(benzimidazole)

 ridinilazole              2,2'-di(pyridin-4-yl)-1H,1'H-5,5'-bi(benzimidazole)

 ridinilazol               2,2'-di(piridin-4-il)-1H,1'H-5,5'-bi(benzoimidazol)

                           C24H16N6
                                                               H
                                                               N
                                                                            N
                                         N                     N
                            N
                                         N
                                         H



 roneparstatum
 roneparstat               heparan sulfate mimetic compound that is obtained by
                           N-des-sulfo and N-acetyl reactions on heparin from porcine
                           intestinal mucosa, sodium periodate glycol split oxidation
                           of uronic acids elements and sodium borohydride reduction
                           of aldehydes produced during oxidation; the majority of the
                           components have a glucuronic acid (coming from the
                           heparin starting material) and glucosamine (formed via
                           decomposition of the glucuronic acid) structure at the non-
                           reducing end and iduronic acid 2-sulphate or glycol split
                           structure at the reducing end of their chain; the average
                           molecular weight range is 15000 to 25000 Da; the degree
                           of glycol split is about 25% [m/(n+m)] and the degree of
                           sulfatation is about 1.2 per disaccharidic unit

 ronéparstat               dérivé à action mimétique du sulfate d’héparane, obtenu
                           par des réactions conduisant à la N-acétyl-
                           N-désulfohéparine de muqueuse intestinale de porc, puis
                           dégradation oxydative des glycols des unités uroniques
                           par le périodate de sodium et réduction, par le borohydrure
                           de sodium, des aldéhydes produits ; la majorité des
                           composants ont, une structure acide glucuronique
                           (présente dans l’héparine de départ) et glucosamine
                           (formé par décomposition de l’acide glucuronique) à leur
                           extrémité non-réductrice et une structure dérivée de l’acide
                           iduronique soit l’ester sulfurique soit sa forme acyclique à
                           leur extrémité réductrice, une masse molaire comprise
                           entre 15000 et 25000 daltons, la proportion d’acide
                           uronique ouvert [m/(n+m)] est d’environ 25% et un degré
                           de sulfatation d’environ de 1.2 par unité disaccharide




418
WHO Drug Information, Vol. 29, No. 3, 2015                                         Recommended INN: List 74


 roneparstat                           derivado de acción mimética de la del sulfato de heparán,
                                       obtenido por reacciones que producen N-acetil-
                                       N-desulfoheparina de mucosa intestinal de cerdo, que se
                                       somete a degradación oxidativa con peryodato de sodio de
                                       los glicoles de las unidades urónicas y a reducción, por
                                       borohidruro de sodio de los aldehídos producidos; la
                                       mayoría de cuyos componentes tienen una estructura de
                                       ácido glucurónico (presente en la heparina de partida) y
                                       glucosamina (formado por descomposición del ácido
                                       glucurónico) en su extremo no-reductor y una estructura
                                       derivada del ácido idurónico que puede ser su éster
                                       sulfúrico o su forma acíclica en su extremo reductor, masa
                                       molar comprendida entre 15000 y 25000 daltons, la
                                       proporción de ácido urónico abierto [m/(n+m)] es de
                                       alrededor de 25% y el grado de sulfatación de alrededor
                                       de 1.2 par unidad de disacárido

                                                    OR1                                             OR1
                                                                   HO2C                                          HO2C
                                                          O                    O                        O                   O
                                        R    O                     O                        O                    O                       O


                                              R1O             NH       HO          O         R1O            NH       HO         OH
                                                     O                      HO3S                    O
                                                              CH3                                           CH3
                                                                                       n                                             m
                                       n =20-22              m = 6-8                                        R1= H or SO3H
                                       R = H , glucosiduronic acid                         R’ = H

 sacrosidasum #
 sacrosidase                           invertase 2 (beta-fructofuranosidase 2, saccharase,
                                       EC=3.2.1.26) from Saccharomyces cerevisiae (strain
                                       ATCC 204508 / S288c, Baker’s yeast)

 sacrosidase                           invertase 2 (bêta-fructofuranosidase 2, saccharase,
                                       EC=3.2.1.26) de Saccharomyces cerevisiae (souche
                                       ATCC 204508 / S288c, levure de boulanger)

 sacrosidasa                           invertasa 2 (beta-fructofuranosidasea 2, sacarasa,
                                       EC=3.2.1.26) de Saccharomyces cerevisiae (cepa ATCC
                                       204508 / S288c, levadura de cerveza)
                                       Sequence / Séquence / Secuencia
                                       SMTNETSDRP LVHFTPNKGW MNDPNGLWYD                     EKDAKWHLYF      QYNPNDTVWG      50
                                       TPLFWGHATS DDLTNWEDQP IAIAPKRNDS                     GAFSGSMVVD      YNNTSGFFND      100
                                       TIDPRQRCVA IWTYNTPESE EQYISYSLDG                     GYTFTEYQKN      PVLAANSTQF      150
                                       RDPKVFWYEP SQKWIMTAAK SQDYKIEIYS                     SDDLKSWKLE      SAFANEGFLG      200
                                       YQYECPGLIE VPTEQDPSKS YWVMFISINP                     GAPAGGSFNQ      YFVGSFNGTH      250
                                       FEAFDNQSRV VDFGKDYYAL QTFFNTDPTY                     GSALGIAWAS      NWEYSAFVPT      300
                                       NPWRSSMSLV RKFSLNTEYQ ANPETELINL                     KAEPILNISN      AGPWSRFATN      350
                                       TTLTKANSYN VDLSNSTGTL EFELVYAVNT                     TQTISKSVFA      DLSLWFKGLE      400
                                       DPEEYLRMGF EVSASSFFLD RGNSKVKFVK                     ENPYFTNRMS      VNNQPFKSEN      450
                                       DLSYYKVYGL LDQNILELYF NDGDVVSTNT                     YFMTTGNALG      SVNMTTGVDN      500
                                       LFYIDKFQVR EVK                                                                       513

                                       Glycosylation sites (potential) / Sites potentiels de glycosylation / Posiciones potenciales de
                                       glicosilación
                                       Asn-4      Asn-45 Asn-78 Asn-92 Asn-99 Asn-146 Asn-247
                                       Asn-256 Asn-337 Asn-350 Asn-365 Asn-379 Asn-493


 sapanisertibum
 sapanisertib                          3-(2-amino-1,3-benzoxazol-5-yl)-1-(propan-2-yl)-
                                       1H-pyrazolo[3,4-d]pyrimidin-4-amine




                                                                                                                                419
Recommended INN: List 74                 WHO Drug Information, Vol. 29, No. 3, 2015



 sapanisertib              3-(2-amino-1,3-benzoxazol-5-yl)-1-(propan-2-yl)-
                           1H-pyrazolo[3,4-d]pyrimidin-4-amine

 sapanisertib              3-(2-amino-1,3-benzoxazol-5-il)-1-(propan-2-il)-
                           1H-pirazolo[3,4-d]pirimidin-4-amina

                           C15H15N7O
                                                                   O
                                                                             NH2
                             H3 C            N                     N
                                         N
                            H3 C
                                                       NH2
                                         N
                                                  N

 seletalisibum
 seletalisib               3-(8-chloro-3-{(1R)-1-[(pyrido[3,2-d]pyrimidin-4-yl)amino]-
                           2,2,2-trifluoroethyl}quinolin-2-yl)pyridine N-oxide

 sélétalisib               N-oxyde de 3-(8-chloro-3-{(1R)-1-[(pyrido[3,2-d]pyrimidin-
                           4-yl)amino]-2,2,2-trifluoroéthyl}quinoléin-2-yl)pyridine

 seletalisib               N-óxido de 3-(8-cloro-3-{(1R)-1-[(pirido[3,2-d]pirimidin-
                           4-il)amino]-2,2,2-trifluoroetil}quinolein-2-il)piridina

                           C23H14ClF3N6O



                                                    N
                                                 H CF3             N

                                                      N       N
                                                      H
                                         N
                                Cl
                                                       N
                                                      O

 setmelanotidum
                            2
 setmelanotide             N -acetyl-L-arginyl-L-cysteinyl-D-alanyl-L-histidyl-
                           D-phenylalanyl-L-arginyl-L-tryptophyl-L-cysteinamide, cyclic
                           (2-8)-disulfide
                                                                       2
 setmélanotide             (2-8)-disulfure cyclique du N -acétyl-L-arginyl-L-cystéinyl-
                           D-alanyl-L-histidyl-D-phénylalanyl-L-arginyl-L-tryptophyl-
                           L-cystéinamide

                                                                   2
 setmelanotida             (2-8)-disulfuro cíclico del N -acetil-L-arginil-L-cisteinil-
                           D-alanil-L-histidil-D-fenilalanil-L-arginil-L-triptofil-
                           L-cisteinamida

                           C49H68N18O9S2

                            H3C
                                         Arg     Cys       D-Ala       His    D-Phe   Arg   Trp   Cys NH2
                                     O




420
WHO Drug Information, Vol. 29, No. 3, 2015                                            Recommended INN: List 74




 solcitinibum
 solcitinib                            N-{5-[4-(3,3-dimethylazetidine-
                                       1-carbonyl)phenyl][1,2,4]triazolo[1,5-a]pyridin-
                                       2-yl}cyclopropanecarboxamide

 solcitinib                            N-{5-[4-(3,3-diméthylazétidine-
                                       1-carbonyl)phényl][1,2,4]triazolo[1,5-a]pyridin-
                                       2-yl}cyclopropanecarboxamide

 solcitinib                            N-{5-[4-(3,3-dimetilazetidina-
                                       1-carbonil)fenil][1,2,4]triazolo[1,5-a]piridin-
                                       2-il}ciclopropanocarboxamida

                                       C22H23N5O2

                                             O
                                                                                         O
                                                         NH
                                                               N                                 N
                                                                                                            CH3
                                                         N      N
                                                                                                        CH3



 somapacitanum #
 somapacitan                           [101-{S-[(8S,22S,27S)-8-carbamoyl-22,27-dicarboxy-
                                       2,10,19,24,29,38,42,42,44-nonaoxo-59-(1H-tetrazol-5-yl)-
                                                                6
                                       12,15,31,34-tetraoxa-42-λ -thia-3,9,18,23,28,37,43-
                                       heptaazanonapentacontyl]-L-cysteine}]human somatropin

 somapacitan                           [101-{S-[(8S,22S,27S)-8-carbamoyl-22,27-dicarboxy-
                                       2,10,19,24,29,38,42,42,44-nonaoxo-59-(1H-tétrazol-5-yl)-
                                                                6
                                       12,15,31,34-tétraoxa-42-λ -thia-3,9,18,23,28,37,43-
                                       heptaazanonapentacontyl]-L-cystéine}]somatropine
                                       humaine

 somapacitán                           [101-{S-[(8S,22S,27S)-8-carbamoil-22,27-dicarboxi-
                                       2,10,19,24,29,38,42,42,44-nonaoxo-59-(1H-tetrazol-5-il)-
                                                                6
                                       12,15,31,34-tetraoxa-42-λ -tia-3,9,18,23,28,37,43-
                                       heptaazanonapentacontil]-L-cisteina}]somatropina humana
                                       Sequence / Séquence / Secuencia
                                       FPTIPLSRLF DNAMLRAHRL HQLAFDTYQE                  FEEAYIPKEQ       KYSFLQNPQT             50
                                       SLCFSESIPT PSNREETQQK SNLELLRISL                  LLIQSWLEPV       QFLRSVFANS             100
                                       CVYGASDSNV YDLLKDLEEG IQTLMGRLED                  GSPRTGQIFK       QTYSKFDTNS             150
                                       HNDDALLKNY GLLYCFRKDM DKVETFLRIV                  QCRSVEGSCG       F                      191

                                       Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro
                                       53-165 182-189

                                       Modified residue / Résidu modifié / Resto modificado

                                                                                             101-Cys =         H2N       CO2H
                                                     N N                                                          H              S
                                                 N                                                                                   CH2
                                                     N
                                                     H                                                                   O
                                          C                                                                                          NH
                                         101                                                 O            HN         O
                                                          O                  O                              S O
                                                                    O                    N
                                                      H                                  H                   O
                                                              NH
                                             HO2C               O   H CO2H                                           O       H
                                                                                     H
                                                                                     N                      O                              NH2
                                                                    N                            O                       N
                                                                    H                                                    H
                                                                                 O                                                   O




                                                                                                                                                 421
Recommended INN: List 74                WHO Drug Information, Vol. 29, No. 3, 2015


 somavaratanum #
 somavaratan               rDNA derived human somatropin (growth hormone of 191
                           residues) fusion protein with a hydrophilic amino acid
                           sequence* (913 residues) at the N-terminus and another**
                           (146 residues) at the C-terminus, produced in Escherichia
                           coli.
                           *starting with alanine plus 76 dodecapeptides:
                           EPAGSPTSTEEG (AE3G2P2S2T2), three different
                           sequences of AG3P2S4T2 and 72 of 4 different sequences
                           of AE2G2P2S3T2
                           ** starting with glycylglycine plus 12 dodecapeptides of 4
                           different sequences of AE2G2P2S3T2

 somavaratan               Protéine de fusion entre la somatropine humaine (facteur
                           de croissance de 191 résidus) et deux protéines
                           hydrophiles, l’une*, de 913 résidus, sur son acide aminé
                           N-terminal, et l’autre**, de 146 résidus, sur son acide
                           aminé C-terminal, obtenue par la technique de l’ADN
                           recombinant à partir de culture d’Escherichia coli.
                           *constituée d’alanine suivie de 76 dodécapeptides,
                           EPAGSPTSTEEG (AE3G2P2S2T2) puis trois différentes
                           séquences de AG3P2S4T2 et 72 de 4 différentes séquences
                           de AE2G2P2S3T2
                           **constituée de glycylglycine suivie de 12 dodécapeptides
                           de 4 différentes séquences de AE2G2P2S3T2

 somavaratán               proteína de fusión entre la somatropina humana (factor de
                           crecimiento 191 restos) y dos proteínas hidrófilas, una*, de
                           913 restos, en el extremo N-terminal, y otra**, de 146
                           restos, en el extremo C-terminal, obtenida por técnicas de
                           ADN recombinante en cultivos d’Escherichia coli.
                           *constituida por alanina seguida de 76 dodecapéptidos,
                           EPAGSPTSTEEG (AE3G2P2S2T2) tres secuencias
                           diferentes de AG3P2S4T2 y 72 de 4 secuencias diferentes
                           de AE2G2P2S3T2
                           **constituida por glicilglicina seguida de 12
                           dodecapéptidos de 4 secuencias diferentes de
                           AE2G2P2S3T2
                           Sequence / Sequence / Secuencia
                           AEPAGSPTST EEGTPGSGTA SSSPGSSTPS                  GATGSPGASP       GTSSTGSPGS       50
                           PAGSPTSTEE GTSESATPES GPGTSTEPSE                  GSAPGSPAGS       PTSTEEGTST       100
                           EPSEGSAPGT STEPSEGSAP GTSESATPES                  GPGSEPATSG       SETPGSEPAT       150
                           SGSETPGSPA GSPTSTEEGT SESATPESGP                  GTSTEPSEGS       APGTSTEPSE       200
                           GSAPGSPAGS PTSTEEGTST EPSEGSAPGT                  STEPSEGSAP       GTSESATPES       250
                           GPGTSTEPSE GSAPGTSESA TPESGPGSEP                  ATSGSETPGT       STEPSEGSAP       300
                           GTSTEPSEGS APGTSESATP ESGPGTSESA                  TPESGPGSPA       GSPTSTEEGT       350
                           SESATPESGP GSEPATSGSE TPGTSESATP                  ESGPGTSTEP       SEGSAPGTST       400
                           EPSEGSAPGT STEPSEGSAP GTSTEPSEGS                  APGTSTEPSE       GSAPGTSTEP       450
                           SEGSAPGSPA GSPTSTEEGT STEPSEGSAP                  GTSESATPES       GPGSEPATSG       500
                           SETPGTSESA TPESGPGSEP ATSGSETPGT                  SESATPESGP       GTSTEPSEGS       550
                           APGTSESATP ESGPGSPAGS PTSTEEGSPA                  GSPTSTEEGS       PAGSPTSTEE       600
                           GTSESATPES GPGTSTEPSE GSAPGTSESA                  TPESGPGSEP       ATSGSETPGT       650
                           SESATPESGP GSEPATSGSE TPGTSESATP                  ESGPGTSTEP       SEGSAPGSPA       700
                           GSPTSTEEGT SESATPESGP GSEPATSGSE                  TPGTSESATP       ESGPGSPAGS       750
                           PTSTEEGSPA GSPTSTEEGT STEPSEGSAP                  GTSESATPES       GPGTSESATP       800
                           ESGPGTSESA TPESGPGSEP ATSGSETPGS                  EPATSGSETP       GSPAGSPTST       850
                           EEGTSTEPSE GSAPGTSTEP SEGSAPGSEP                  ATSGSETPGT       SESATPESGP       900
                           GTSTEPSEGS APGFPTIPLS RLFDNAMLRA                  HRLHQLAFDT       YQEFEEAYIP       950
                           KEQKYSFLQN PQTSLCFSES IPTPSNREET                  QQKSNLELLR       ISLLLIQSWL       1000
                           EPVQFLRSVF ANSLVYGASD SNVYDLLKDL                  EEGIQTLMGR       LEDGSPRTGQ       1050
                           IFKQTYSKFD TNSHNDDALL KNYGLLYCFR                  KDMDKVETFL       RIVQCRSVEG       1100
                           SCGFGGTSES ATPESGPGTS TEPSEGSAPG                  TSTEPSEGSA       PGTSESATPE       1150
                           SGPGTSTEPS EGSAPGTSTE PSEGSAPGTS                  ESATPESGPG       TSTEPSEGSA       1200
                           PGTSTEPSEG SAPGTSTEPS EGSAPGSPAG                  SPTSTEEGTS       TEPSEGSAPG       1250

                           Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro
                           966-1078 1095-1102




422
WHO Drug Information, Vol. 29, No. 3, 2015                          Recommended INN: List 74


 spanlecortemlocelum
 spanlecortemlocel                     Consists of human expanded CD34+ haematopoietic stem
                                       cells that have been isolated from umbilical cord blood and
                                       cultured in vitro in media supplemented with THPO
                                       (thrombopoietin), KITLG (KIT ligand, stem cell factor,
                                       SCF), IL6 (interleukin 6), FLT3LG (fms-related tyrosine
                                       kinase 3 (FLT3) ligand), and an antagonist of AHR (aryl
                                       hydrocarbon receptor); typically contains >10% of cells
                                       expressing CD34

 spanlécortemlocel                     cellules souches hématopoïétiques humaines exprimant
                                       CD34+ isolées du sang de cordon ombilical et mises en
                                       culture in vitro en milieu enrichi en THPO
                                       (thrombopoïétine), KITLG (ligand de KIT, facteur de
                                       cellules souches, SCF), IL6 (interleukine 6), FLT3LG
                                       (ligand de tyrosine kinase 3 fms-like (FLT3)) et un
                                       antagoniste d’AHR (récepteur des hydrocarbures
                                       aromatiques); typiquement, contient >10% de cellules
                                       exprimant CD34

 espanlecortemlocel                    células madre hematopoyéticas humanas que expresan
                                       CD34+ aisladas de sangre de cordón umbilical y cultivadas
                                       in vitro en un medio enriquecido en THPO
                                       (trombopoyetina), KITLG (ligante de KIT, factor de células
                                       madre, SCF), IL6 (interleukina 6), FLT3LG (ligando de
                                       tirosina kinasa 3 fms-like (FLT3)) y un antagonista de AHR
                                       (receptor de hidrocarburos arílicos); normalmente,
                                       contiene >10% de células que expresan CD34


 spebrutinibum
 spebrutinib                           N-[3-({5-fluoro-2-[4-(2-methoxyethoxy)anilino]pyrimidin-
                                       4-yl}amino)phenyl]prop-2-enamide

 spébrutinib                           N-[3-({5-fluoro-2-[4-(2-méthoxyéthoxy)anilino]pyrimidin-
                                       4-yl}amino)phényl]prop-2-énamide

 espebrutinib                          N-[3-({5-fluoro-2-[4-(2-metoxietoxi)anilino]pirimidin-
                                       4-il}amino)fenil]prop-2-enamida

                                       C22H22FN5O3

                                                                         F
                                                    H           H
                                                    N           N
                                        H2C
                                                O                   N        N

                                                                        HN

                                                                                            O
                                                                                  O             CH3


 susoctocogum alfa #
 susoctocog alfa                       recombinant DNA derived B-domain deleted porcine blood-
                                       coagulation factor VIII analogue, produced in BHK21 cells:
                                       des-(753-1418)-blood-coagulation factor VIII (procoagulant
                                       component) Sus scrofa, glycosylated




                                                                                                  423
Recommended INN: List 74                WHO Drug Information, Vol. 29, No. 3, 2015




 susoctocog alfa           analogue du facteur de coagulation VIII porcin dont le
                           domaine B a été supprimé, produit dans des cellules
                           BHK21, à partir d'ADN recombinant:
                           dès-(753-1418)-facteur VIII de coagulation (composant
                           procoagulant) de Sus scrofa (porc), glycosylé

 susoctocog alfa           análogo del factor de coagulación VIII porcino del cual se
                           ha suprimido el dominio B, producido en células BHK21, a
                           partir de ADN recombinante:
                           des-(753-1418)-factor VIII de coagulación (componente
                           procoagulante) de Sus scrofa (cerdo) glicosilado


                           Sequence / Séquence / Secuencia
                           AIRRYYLGAV ELSWDYRQSE LLRELHVDTR                  FPATAPGALP       LGPSVLYKKT       50
                           VFVEFTDQLF SVARPRPPWM GLLGPTIQAE                  VYDTVVVTLK       NMASHPVSLH       100
                           AVGVSFWKSS EGAEYEDHTS QREKEDDKVL                  PGKSQTYVWQ       VLKENGPTAS       150
                           DPPCLTYSYL SHVDLVKDLN SGLIGALLVC                  REGSLTRERT       QNLHEFVLLF       200
                           AVFDEGKSWH SARNDSWTRA MDPAPARAQP                  AMHTVNGYVN       RSLPGLIGCH       250
                           KKSVYWHVIG MGTSPEVHSI FLEGHTFLVR                  HHRQASLEIS       PLTFLTAQTF       300
                           LMDLGQFLLF CHISSHHHGG MEAHVRVESC                  AEEPQLRRKA       DEEEDYDDNL       350
                           YDSDMDVVRL DGDDVSPFIQ IRSVAKKHPK                  TWVHYISAEE       EDWDYAPAVP       400
                           SPSDRSYKSL YLNSGPQRIG RKYKKARFVA                  YTDVTFKTRK       AIPYESGILG       450
                           PLLYGEVGDT LLIIFKNKAS RPYNIYPHGI                  TDVSALHPGR       LLKGWKHLKD       500
                           MPILPGETFK YKWTVTVEDG PTKSDPRCLT                  RYYSSSINLE       KDLASGLIGP       550
                           LLICYKESVD QRGNQMMSDK RNVILFSVFD                  ENQSWYLAEN       IQRFLPNPDG       600
                           LQPQDPEFQA SNIMHSINGY VFDSLQLSVC                  LHEVAYWYIL       SVGAQTDFLS       650
                           VFFSGYTFKH KMVYEDTLTL FPFSGETVFM                  SMENPGLWVL       GCHNSDLRNR       700
                           GMTALLKVYS CDRDIGDYYD NTYEDIPGFL                  LSGKNVIEPR       SFAQNSRPPS       750
                           ASAPKPPVLR RHQRDISLPT FQPEEDKMDY                  DDIFSTETKG       EDFDIYGEDE       800
                           NQDPRSFQKR TRHYFIAAVE QLWDYGMSES                  PRALRNRAQN       GEVPRFKKVV       850
                           FREFADGSFT QPSYRGELNK HLGLLGPYIR                  AEVEDNIMVT       FKNQASRPYS       900
                           FYSSLISYPD DQEQGAEPRH NFVQPNETRT                  YFWKVQHHMA       PTEDEFDCKA       950
                           WAYFSDVDLE KDVHSGLIGP LLICRANTLN                  AAHGRQVTVQ       EFALFFTIFD       1000
                           ETKSWYFTEN VERNCRAPCH LQMEDPTLKE                  NYRFHAINGY       VMDTLPGLVM       1050
                           AQNQRIRWYL LSMGSNENIH SIHFSGHVFS                  VRKKEEYKMA       VYNLYPGVFE       1100
                           TVEMLPSKVG IWRIECLIGE HLQAGMSTTF                  LVYSKECQAP       LGMASGRIRD       1150
                           FQITASGQYG QWAPKLARLH YSGSINAWST                  KDPHSWIKVD       LLAPMIIHGI       1200
                           MTQGARQKFS SLYISQFIIM YSLDGRNWQS                  YRGNSTGTLM       VFFGNVDASG       1250
                           IKHNIFNPPI VARYIRLHPT HYSIRSTLRM                  ELMGCDLNSC       SMPLGMQNKA       1300
                           ISDSQITASS HLSNIFATWS PSQARLHLQG                  RTNAWRPRVS       SAEEWLQVDL       1350
                           QKTVKVTGIT TQGVKSLLSS MYVKEFLVSS                  SQDGRRWTLF       LQDGHTKVFQ       1400
                           GNQDSSTPVV NALDPPLFTR YLRIHPTSWA                  QHIALRLEVL       GCEAQDLY         1448

                           Disulfide bridges location / Positions des ponts disulfure / Posiciones de los puentes disulfuro
                           154-180 249-330 528-554 630-711 948-974 1015-1019 1137-1285 1290-1442

                           Modified residues / Résidus modifiés / Restos modificados

                                       Y                     HO    O
                            346-718-719-723-780-796              S                  H   NH2
                                   O-sulfoTyr
                                                                O O
                                                                                         CO2H

                           Glycosylation sites (N,S,T) / Sites de glycosylation (N,S,T) / Posiciones de glicosilación
                           (N,S,T)
                           Ser-44 Asn-214 Asn-240 Ser-353 Asn-582
                           Ser-741 Ser-752 Thr-770 Asn-926 Asn-1234



 tazemetostatum
 tazemetostat              N-[(4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl]-
                           5-[ethyl(oxan-4-yl)amino]-4-methyl-4'-[(morpholin-
                           4-yl)methyl][1,1'-biphenyl]-3-carboxamide

 tazémétostat              N-[(4,6-diméthyl-2-oxo-1,2-dihydropyridin-3-yl)méthyl]-
                           5-[éthyl(oxan-4-yl)amino]-4-méthyl-4'-[(morpholin-
                           4-yl)méthyl][1,1'-biphényl]-3-carboxamide

 tazemetostat              N-[(4,6-dimetil-2-oxo-1,2-dihidropiridin-3-il)metil]-
                           5-[etil(oxan-4-il)amino]-4-metil-4'-[(morfolin-4-il)metil][1,1'-
                           bifenil]-3-carboxamida




424
WHO Drug Information, Vol. 29, No. 3, 2015                             Recommended INN: List 74


                                       C34H44N4O4

                                              N                            O               CH3
                                        O
                                                                               N
                                                                               H
                                                                           CH3     O       N     CH3
                                                                                           H
                                                          H3C      N

                                                                               O


 temsavirum
 temsavir                              1-(4-benzoylpiperazin-1-yl)-2-[4-methoxy-7-(3-methyl-
                                       1H-1,2,4-triazol-1-yl)-1H-pyrrolo[2,3-c]pyridin-3-yl]ethane-
                                       1,2-dione

 temsavir                              1-(4-benzoylpipérazin-1-yl)-2-[4-méthoxy-7-(3-méthyl-
                                       1H-1,2,4-triazol-1-yl)-1H-pyrrolo[2,3-c]pyridin-3-yl]éthane-
                                       1,2-dione

 temsavir                              1-(4-benzoilpiperazin-1-il)-2-[4-metoxi-7-(3-metil-1H-1,2,4-
                                       triazol-1-il)-4-metoxi-1H-pirrolo[2,3-c]piridin-3-il]etano-
                                       1,2-diona

                                       C24H23N7O4

                                                  N
                                        H3C
                                                          HN           O
                                               N N

                                                                           N
                                                      N
                                                                   O               N
                                                                OCH3
                                                                                       O

 tesidolumabum #
 tesidolumab                           immunoglobulin G1-lambda2, anti-[Homo sapiens C5
                                       (complement C5)], Homo sapiens monoclonal antibody;
                                       gamma1 heavy chain (1-446) [Homo sapiens VH (IGHV1-
                                       69*01 (96.90%) -(IGHD)-IGHJ4*01) [8.8.9] (1-116) -
                                       IGHG1*03 (CH1 (117-214), hinge (215-229), CH2 (230-
                                       339) L1.3>A (233), L1.2>A (234), CH3 (340-444), CHS
                                       (445-446) (117-446)], (219-213')-disulfide with lambda2
                                       light chain (1'-214') [Homo sapiens V-LAMBDA (IGLV3-
                                       9*01 (88.20%) -IGLJ2*01) [6.3.11] (1'-108') -IGLC2*01
                                       (109'-214')]; dimer (225-225'':228-228'')-bisdisulfide

 tésidolumab                           immunoglobuline G1-lambda2, anti-[Homo sapiens C5
                                       (complément C5)], Homo sapiens anticorps monoclonal;
                                       chaîne lourde gamma1 (1-446) [Homo sapiens VH
                                       (IGHV1-69*01 (96.90%) -(IGHD)-IGHJ4*01) [8.8.9] (1-116)
                                       -IGHG1*03 (CH1 (117-214), charnière (215-229), CH2
                                       (230-339) L1.3>A (233), L1.2>A (234), CH3 (340-444),
                                       CHS (445-446) (117-446)], (219-213')-disulfure avec la
                                       chaîne légère lambda2 (1'-214') [Homo sapiens
                                       V-LAMBDA (IGLV3-9*01 (88.20%) -IGLJ2*01) [6.3.11]
                                       (1'-108') -IGLC2*01 (109'-214')]; dimère (225-225'':228-
                                       228'')-bisdisulfure



                                                                                                       425
Recommended INN: List 74                WHO Drug Information, Vol. 29, No. 3, 2015




 tesidolumab               inmunoglobulina G1-lambda2, anti-[C5 (complemento C5)
                           de Homo sapiens], anticuerpo monoclonal de Homo
                           sapiens;
                           cadena pesada gamma1 (1-446) [Homo sapiens VH
                           (IGHV1-69*01 (96.90%) -(IGHD)-IGHJ4*01) [8.8.9] (1-116)
                           -IGHG1*03 (CH1 (117-214), bisagra (215-229), CH2 (230-
                           339) L1.3>A (233), L1.2>A (234), CH3 (340-444), CHS
                           (445-446) (117-446)], (219-213')-disulfuro con la cadena
                           ligera lambda2 (1'-214') [Homo sapiens V-LAMBDA
                           (IGLV3-9*01 (88.20%) -IGLJ2*01) [6.3.11] (1'-108') -
                           IGLC2*01 (109'-214')]; dímero (225-225'':228-228'')-
                           bisdisulfuro


                           Heavy chain / Chaîne lourde / Cadena pesada
                           EVQLVQSGAE VKKPGSSVKV SCKASGGTFS                  SYAISWVRQA       PGQGLEWMGG        50
                           IGPFFGTANY AQKFQGRVTI TADESTSTAY                  MELSSLRSED       TAVYYCARDT       100
                           PYFDYWGQGT LVTVSSASTK GPSVFPLAPS                  SKSTSGGTAA       LGCLVKDYFP       150
                           EPVTVSWNSG ALTSGVHTFP AVLQSSGLYS                  LSSVVTVPSS       SLGTQTYICN       200
                           VNHKPSNTKV DKRVEPKSCD KTHTCPPCPA                  PEAAGGPSVF       LFPPKPKDTL       250
                           MISRTPEVTC VVVDVSHEDP EVKFNWYVDG                  VEVHNAKTKP       REEQYNSTYR       300
                           VVSVLTVLHQ DWLNGKEYKC KVSNKALPAP                  IEKTISKAKG       QPREPQVYTL       350
                           PPSREEMTKN QVSLTCLVKG FYPSDIAVEW                  ESNGQPENNY       KTTPPVLDSD       400
                           GSFFLYSKLT VDKSRWQQGN VFSCSVMHEA                  LHNHYTQKSL       SLSPGK           446

                           Light chain / Chaîne légère / Cadena ligera
                           SYELTQPLSV SVALGQTARI TCSGDSIPNY                  YVYWYQQKPG       QAPVLVIYDD 50
                           SNRPSGIPER FSGSNSGNTA TLTISRAQAG                  DEADYYCQSF       DSSLNAEVFG 100
                           GGTKLTVLGQ PKAAPSVTLF PPSSEELQAN                  KATLVCLISD       FYPGAVTVAW 150
                           KADSSPVKAG VETTTPSKQS NNKYAASSYL                  SLTPEQWKSH       RSYSCQVTHE 200
                           GSTVEKTVAP TECS                                                               214

                           Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro
                           Intra-H (C23-C104) 22-96         143-199       260-320    366-424
                                                 22''-96'' 143''-199'' 260''-320'' 366''-424''
                           Intra-L (C23-C104) 22'-87' 136'-195'
                                                22'''-87''' 136'''-195'''
                           Inter-H-L (h 5-CL 126) 219-213' 219''-213'''
                           Inter-H-H (h 11, h 14) 225-225'' 228-228''

                           N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación
                           H CH2 N84.4:
                           296, 296''



 toreforantum
 toreforant                5-(4,6-dimethyl-1H-benzimidazol-2-yl)-4-methyl-
                           N-[3-(1-methylpiperidin-4-yl)propyl]pyrimidin-2-amine

 toréforant                5-(4,6-diméthyl-1H-benzimidazol-2-yl)-4-méthyl-
                           N-[3-(1-méthylpipéridin-4-yl)propyl]pyrimidin-2-amine

 toreforant                5-(4,6-dimetil-1H-benzoimidazol-2-il)-4-metil-
                           N-[3-(1-metilpiperidin-4-il)propil]pirimidin-2-amina

                           C23H32N6

                                                                                                         CH3
                                                                                                     N
                                                                        H
                                                               N        N
                                                H
                                                N                  N

                            H 3C                     N         CH3


                                               CH3




426
WHO Drug Information, Vol. 29, No. 3, 2015                            Recommended INN: List 74




 trofinetidum
 trofinetide                           glycyl-2-methyl-L-prolyl-L-glutamic acid

 trofinétide                           acide glycyl-2-méthyl-L-prolyl-L-glutamique

 trofinetida                           ácido glicil-2-metil-L-prolil-L-glutámico

                                       C13H21N3O6

                                                     O              CO2H
                                        H2N              O      H
                                                 N
                                                            N   CO2H
                                                         CH3H



 vandortuzumabum vedotinum #
 vandortuzumab vedotin                 immunoglobulin G1-kappa, anti-[Homo sapiens STEAP1
                                       (six-transmembrane epithelial antigen of the prostate 1,
                                       PRSS24, STEAP)], humanized monoclonal antibody;
                                       gamma1 heavy chain (1-454) [humanized VH (Homo
                                       sapiens IGHV3-48*03 (80.80%) -(IGHD)-IGHJ4*01)
                                       [9.7.17] (1-124) -Homo sapiens IGHG1*03 (CH1 R120>K
                                       (221) (125-222), hinge (223-237),CH2 (238-347), CH3
                                       (348-452), CHS (453-454)) (125-454)], (227-220')-disulfide
                                       with kappa light chain (1’-220’) [humanized V-KAPPA
                                       (Homo sapiens IGKV1-16*01 (81.20%) -IGKJ1*01) [12.3.9]
                                       (1'-113') -Homo sapiens IGKC*01 (114'-220')]; dimer (233-
                                       233":236-236")-bisdisulfide; conjugated, on an average of
                                       3 to 4 cysteinyl, to monomethylauristatin E (MMAE), via a
                                       cleavable maleimidocaproyl-valyl-citrullinyl-
                                       p-aminobenzyloxycarbonyl (mc-val-cit-PABC) type linker
                                       For the vedotin part, please refer to the document “INN for
                                       pharmaceutical substances: Names for radicals, groups
                                       and others”*.

 vandortuzumab védotine                immunoglobuline G1-kappa, anti-[Homo sapiens STEAP1
                                       (antigène épithélial 1 à six-transmembrane de la prostate,
                                       PRSS24, STEAP)], anticorps monoclonal humanisé;
                                       chaîne lourde gamma1(1-454) [VH humanisé (Homo
                                       sapiens IGHV3-48*03 (80.80%) -(IGHD)-IGHJ4*01)
                                       [9.7.17] (1-124) -Homo sapiens IGHG1*03 (CH1 R120>K
                                       (221) (125-222), charnière (223-237),CH2 (238-347), CH3
                                       (348-452), CHS (453-454)) (125-454)], (227-220')-disulfure
                                       avec la chaîne légère kappa (1’-220’) [V-KAPPA humanisé
                                       (Homo sapiens IGKV1-16*01 (81.20%) -IGKJ1*01) [12.3.9]
                                       (1'-113') -Homo sapiens IGKC*01 (114'-220')]; dimère
                                       (233-233":236-236")-bisdisulfure; conjugué, sur 3 à 4
                                       cystéinyl en moyenne, au monométhylauristatine E
                                       (MMAE), via un linker clivable de type maléimidocaproyl-
                                       valyl-citrullinyl-p-aminobenzyloxycarbonyl (mc-val-cit-
                                       PABC)
                                       Pour la partie védotine, veuillez-vous référer au document
                                       “INN for pharmaceutical substances: Names for radicals,
                                       groups and others”*.




                                                                                              427
Recommended INN: List 74                 WHO Drug Information, Vol. 29, No. 3, 2015




 vandortuzumab vedotina    inmunoglobulina G1-kappa, anti-[STEAP1 de Homo
                           sapiens (antígeno epitelial 1 seis-transmembrana de la
                           próstata, PRSS24, STEAP)], anticuerpo monoclonal
                           humanizado;
                           cadena pesada gamma1 (1-454) [VH humanizada (Homo
                           sapiens IGHV3-48*03 (80.80%) -(IGHD)-IGHJ4*01)
                           [9.7.17] (1-124) -Homo sapiens IGHG1*03 (CH1 R120>K
                           (221) (125-222), bisagra (223-237),CH2 (238-347), CH3
                           (348-452), CHS (453-454)) (125-454)], (227-220')-disulfuro
                           con la cadena ligera kappa (1’-220’) [V-KAPPA
                           humanizado (Homo sapiens IGKV1-16*01 (81.20%) -
                           IGKJ1*01) [12.3.9] (1'-113') -Homo sapiens IGKC*01 (114'-
                           220')]; dímero (233-233":236-236")-bisdisulfuro;
                           conjugado, en 3 – 4 restos cisteinil por término medio , con
                           monometilauristatina E (MMAE), mediante una secuencia
                           de conexión escindible de tipo maleimidocaproil-valil-
                           citrulinil-p-aminobenciloxicarbonil (mc-val-cit-PABC)
                           La fracción vedotina pueden encontrarla en el documento
                           “INN for pharmaceutical substances: Names for radicals,
                           groups and others”*.
                           Heavy chain / Chaîne lourde / Cadena pesada
                           EVQLVESGGG LVQPGGSLRL SCAVSGYSIT                  SDYAWNWVRQ       APGKGLEWVG        50
                           YISNSGSTSY NPSLKSRFTI SRDTSKNTLY                  LQMNSLRAED       TAVYYCARER       100
                           NYDYDDYYYA MDYWGQGTLV TVSSASTKGP                  SVFPLAPSSK       STSGGTAALG       150
                           CLVKDYFPEP VTVSWNSGAL TSGVHTFPAV                  LQSSGLYSLS       SVVTVPSSSL       200
                           GTQTYICNVN HKPSNTKVDK KVEPKSCDKT                  HTCPPCPAPE       LLGGPSVFLF       250
                           PPKPKDTLMI SRTPEVTCVV VDVSHEDPEV                  KFNWYVDGVE       VHNAKTKPRE       300
                           EQYNSTYRVV SVLTVLHQDW LNGKEYKCKV                  SNKALPAPIE       KTISKAKGQP       350
                           REPQVYTLPP SREEMTKNQV SLTCLVKGFY                  PSDIAVEWES       NGQPENNYKT       400
                           TPPVLDSDGS FFLYSKLTVD KSRWQQGNVF                  SCSVMHEALH       NHYTQKSLSL       450
                           SPGK                                                                                454
                           Light chain / Chaîne légère / Cadena ligera
                           DIQMTQSPSS LSASVGDRVT ITCKSSQSLL                  YRSNQKNYLA       WYQQKPGKAP 50
                           KLLIYWASTR ESGVPSRFSG SGSGTDFTLT                  ISSLQPEDFA       TYYCQQYYNY 100
                           PRTFGQGTKV EIKRTVAAPS VFIFPPSDEQ                  LKSGTASVVC       LLNNFYPREA 150
                           KVQWKVDNAL QSGNSQESVT EQDSKDSTYS                  LSSTLTLSKA       DYEKHKVYAC 200
                           EVTHQGLSSP VTKSFNRGEC                                                         220

                           Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro
                           Intra-H (C23-C104) 22-96          151-207       268-328   374-432
                                                 22''-96'' 151''-207'' 268''-328'' 374''-432''
                           Intra-L (C23-C104) 23'-94'         140'-200'
                                                 23'''-94''' 140'''-200'''
                           Inter-H-L* (h 5-CL 126) 227-220' 227''-220'''
                           Inter-H-H* (h 11, h 14) 233-233'' 236-236''
                           *Two or three of the inter-chain disulfide bridges are not present, an average of 3 to 4
                           cysteinyl being conjugated each via a thioether bond to a drug linker.
                           *Deux ou trois des ponts disulfures inter-chaînes ne sont pas présents, 3 à 4 cystéinyl en
                           moyenne étant chacun conjugué via une liaison thioéther à un linker-principe actif.
                           *Faltan dos o tres puentes disulfuro inter-catenarios, una media de 3 a 4 cisteinil está
                           conjugada a conectores de principio activo.

                           N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación
                           H CH2 N84.4:
                           304, 304'




 verosudilum
 verosudil                 rac-(2R)-2-(dimethylamino)-N-(1-oxo-
                           1,2-dihydroisoquinolin-6-yl)-2-(thiophen-3-yl)acetamide

 vérosudil                 rac-(2R)-2-(diméthylamino)-N-(1-oxo-
                           1,2-dihydroisoquinoléin-6-yl)-2-(thiophén-3-yl)acétamide

 verosudil                 rac-(2R)-2-(dimetilamino)-N-(1-oxo-1,2-dihidroisoquinolein-
                           6-il)-2-(tiofen-3-il)acetamida




428
WHO Drug Information, Vol. 29, No. 3, 2015                                       Recommended INN: List 74


                                       C17H17N3O2S

                                                                                         O

                                                         CH3       O                         NH
                                        rac              N
                                              H3 C                     N
                                                                       H
                                                               H
                                                S


 verubecestatum
 verubecestat                          N-{3-[(5R)-3-amino-2,5-dimethyl-1,1-dioxo-1,2,5,6-
                                                     6
                                       tetrahydro-1λ ,2,4-thiadiazin-5-yl]-4-fluorophenyl}-
                                       5-fluoropyridine-2-carboxamide

 vérubécestat                          N-{3-[(5R)-3-amino-2,5-diméthyl-1,1-dioxo-1,2,5,6-
                                                     6
                                       tétrahydro-1λ ,2,4-thiadiazin-5-yl]-4-fluorophényl}-
                                       5-fluoropyridine-2-carboxamide

 verubecestat                          N-{3-[(5R)-3-amino-2,5-dimetil-1,1-dioxo-1,2,5,6-tetrahidro-
                                         6
                                       1λ ,2,4-tiadiazin-5-il]-4-fluorofenil}-5-fluoropiridina-
                                       2-carboxamida
                                        C17H17F2N5O3S

                                                                                         O
                                        F                                                    O
                                                     N                                   S
                                                               H           H3C
                                                               N                             N CH3
                                                                                     N
                                                          O                                  NH2
                                                                                 F

 vosoritidum
 vosoritide                            A modified recombinant human C-type natriuretic peptide
                                       (CNP) consisting of 39 amino acids comprised of the 37
                                       C-terminal amino acids of the human CNP sequence plus
                                       the addition of 2 amino acids (Pro-Gly) on the N-terminus,
                                       produced in Escherichia coli:
                                       L-prolylglycyl-(human C-type natriuretic peptide-(17-53)-
                                       peptide (CNP-37)), cyclic-(23-39)-disulfide

 vosoritide                            peptide natriurétique de type C humain modifié consistant
                                       en une séquence de 39 acides aminés comprenant les 37
                                       acides aminés C-terminaux du peptide humain CNP plus
                                       deux acides aminés (Pro-Gly) N-terminaux, produit par
                                       Escherichia coli:
                                       L-prolylglycyl-(peptide natriurétique de type C humain-
                                       (17-53)-peptide (CNP-37)), (23-39)-disulfure cyclique

 vosoritida                            péptido natriurético de tipo C humano modificado
                                       consistente en una secuencia de 39 aminoácidos que
                                       comprende los 37 aminoácidos C-terminales del péptido
                                       humano CNP más dos aminoácidos (Pro-Gly)
                                       N-terminales, producido por Escherichia coli:
                                       L-prolilglicil-(péptido natriurético de tipo C humano-(17-53)-
                                       péptido (CNP-37)), (23-39)-disulfuro cíclico




                                                                                                     429
Recommended INN: List 74                                   WHO Drug Information, Vol. 29, No. 3, 2015


                                               C176H290N56O51S3
                                               Sequence / Séquence / Secuencia
                                               PGQEHPNARK YKGANKKGLS KGCFGLKLDR IGSMSGLGC                         39

                                               Disulfide bridge location / Position du pont disulfure / Posición del puente disulfuro
                                               23-39


  zuretinoli acetas
  zuretinol acetate                           (2E,4E,6Z,8E)-3,7-dimethyl-9-(2,6,6-trimethylcyclohex-
                                              1-en-1-yl)nona-2,4,6,8-tetraen-1-yl acetate

  acétate de zurétinol                        acétate de (2E,4E,6Z,8E)-3,7-diméthyl-9-(2,6,6-
                                              triméthylcyclohex-1-én-1-yl)nona-2,4,6,8-tétraén-1-yle

  acetato de zuretinol                        acetato de (2E,4E,6Z,8E)-3,7-dimetil-9-(2,6,6-
                                              trimetilciclohex-1-en-1-il)nona-2,4,6,8-tetraen-1-ilo

                                               C22H32O2

                                                H3C     CH3           CH3




                                                              CH3

                                                                       H3C                  O

                                                                                        O       CH3




# Electronic structure available on Mednet: http://mednet.who.int/
# Structure électronique disponible sur Mednet: http://mednet.who.int/
# Estructura electrónica disponible en Mednet: http://mednet.who.int/

* http://www.who.int/medicines/services/inn/publication/en/




430
WHO Drug Information, Vol. 29, No. 3, 2015                                        Recommended INN: List 74




                         AMENDMENTS TO PREVIOUS LISTS
                MODIFICATIONS APPORTÉES AUX LISTES ANTÉRIEURES
                    MODIFICACIONES A LAS LISTAS ANTERIORES


Recommended International Nonproprietary Names (Rec. INN): List 29
Dénominations communes internationales recommandées (DCI Rec.): Liste 29
Denominaciones Comunes Internacionales recomendadas (DCI Rec.): Lista 29
(WHO Drug Information, Vol. 3, No. 3, 1989)

p. 7   natrii pentosani polysulfas
       pentosan polysulfate sodium             replace the chemical name, the molecular formula by the
                                               following ones and insert the following structure
       pentosane polysulfate sodique           remplacer le nom chimique, la formule moléculaire par les
                                               suivants et insérer la structure suivante
       pentosano polisulfato de sodio          sustitúyase el nombre químico, la fórmula molecular por los
                                               siguientes y insértese la estructura siguiente

                      a mixture of the sodium salts of linear polymers of (1→4)-β-D-xylopyranan usually
                      sulfated at the 2-and 3-positions and occasionally (approximately 1 in every 10
                      residues) substituted at the 2-position with a (4-O-methyl-
                      2,3-di-O-sulfo-α-D-glucopyranosyluronic acid) group; the average molecular
                      weight lies between 4000 and 6000 with a total molecular weight range of 1000
                      to 40000

                      un mélange de sels de sodium de polymères linéaires de
                      (1→4)-β-D-xylopyranane habituellement sulfatés en positions 2 et 3 et parfois
                      (approximativement 1 résidu sur 10) substitué en position 2 avec un groupe
                      acide 4-O-méthyl-2,3-di-O-sulfo-α-D-glucopyranosyluronique; le poids
                      moléculaire moyen est compris entre 4000 et 6000 avec un poids moléculaire
                      total compris entre 1000 et 40000

                      una mezcla de sales sódicas de polímeros lineales de (1→4)-β-D-xilopiranano
                      generalmente sulfatados en posiciones 2 y 3 y ocasionalmente
                      (aproximadamente 1 resto cada 10) sustituido en posición 2 por un grupo ácido
                      4-O-metil-2,3-di-O-sulfo-α-D-glucopiranosilurónico; el peso molecular medio está
                      comprendido entre 4000 y 6000 con un peso molecular total comprendido entre
                      1000 y 40000

                      (C5H6Na2O10S2)n (C7H8Na2O9S)0.1n (Na2O7S2), average n = ca 11 to 16

                                  O                             O                              *
                                                    O
                      Na   + -O   S    O                    O   S    -
                                                                    O Na   +                            OSO3- Na+
                                                                                           O
                                  O                             O
                                           O            O                R = Na+ -O
                                                                                                        OSO3- Na+
                                                                                      O
                                       O   S    O       R                                      OCH3

                                           O- Na+                                     or   * SO3- Na+
                                                            n

                                      chain length n = ca. 11-16                      ratio = ca. 1:9                
                       




                                                                                                                        431
Recommended INN: List 74                            WHO Drug Information, Vol. 29, No. 3, 2015




  Procedure and Guiding Principles / Procédure et Directives / Procedimientos y principios
  generales
  The text of the Procedures for the Selection of Recommended International Nonproprietary Names
  for Pharmaceutical Substances and General Principles for Guidance in Devising International
  Nonproprietary Names for Pharmaceutical Substances will be reproduced in proposed INN lists
  only.
  Les textes de la Procédure à suivre en vue du choix de dénominations communes internationales
  recommandées pour les substances pharmaceutiques et des Directives générales pour la
  formation de dénominations communes internationales applicables aux substances
  pharmaceutiques seront publiés seulement dans les listes des DCI proposées.
  El texto de los Procedimientos de selección de denominaciones comunes internacionales
  recomendadas para las sustancias farmacéuticas y de los Principios generales de orientación para
  formar denominaciones comunes internacionales para sustancias farmacéuticas aparece
  solamente en las listas de DCI propuestas.




432
